Targeting lipid mediators in cancer biology

go back to reference Wang, D., & Dubois, R. N. (2010). Eicosanoids and cancer. Nature Reviews. Cancer, 10(3), 181–193.PubMedCentralCrossRefPubMed Wang, D., & Dubois, R. N. (2010). Eicosanoids and cancer. Nature Reviews. Cancer, 10(3), 181–193.PubMedCentralCrossRefPubMed

go back to reference Krishnamoorthy, S., & Honn, K. V. (2011). Eicosanoids and other lipid mediators and the tumor hypoxic microenvironment. Cancer Metastasis Reviews, 30, 613–618.CrossRefPubMed Krishnamoorthy, S., & Honn, K. V. (2011). Eicosanoids and other lipid mediators and the tumor hypoxic microenvironment. Cancer Metastasis Reviews, 30, 613–618.CrossRefPubMed

go back to reference van Meer, G. (2005). Cellular lipidomics. The EMBO Journal, 24(18), 3159–3165.PubMedCentralCrossRefPubMed van Meer, G. (2005). Cellular lipidomics. The EMBO Journal, 24(18), 3159–3165.PubMedCentralCrossRefPubMed

go back to reference Yan, G., Li, L., Zhu, B., & Li, Y. (2016). Lipidome in colorectal cancer. Oncotarget, 7(22), 33429–33439.PubMedCentralCrossRefPubMed Yan, G., Li, L., Zhu, B., & Li, Y. (2016). Lipidome in colorectal cancer. Oncotarget, 7(22), 33429–33439.PubMedCentralCrossRefPubMed

go back to reference Fahy, E., Subramaniam, S., Murphy, R. C., Nishijima, M., Raetz, C. R. H., Shimizu, T., Spener, F., van Meer, G., Wakelam, M. J. O., & Dennis, E. A. (2009). Update of the LIPID MAPS comprehensive classification system for lipids. Journal of Lipid Research, 50(Suppl), S9–S14.PubMedCentralCrossRefPubMed Fahy, E., Subramaniam, S., Murphy, R. C., Nishijima, M., Raetz, C. R. H., Shimizu, T., Spener, F., van Meer, G., Wakelam, M. J. O., & Dennis, E. A. (2009). Update of the LIPID MAPS comprehensive classification system for lipids. Journal of Lipid Research, 50(Suppl), S9–S14.PubMedCentralCrossRefPubMed

go back to reference Santos, C. R., & Schulze, A. (2012). Lipid metabolism in cancer. The FEBS Journal, 279(15), 2610–2623.CrossRefPubMed Santos, C. R., & Schulze, A. (2012). Lipid metabolism in cancer. The FEBS Journal, 279(15), 2610–2623.CrossRefPubMed

go back to reference Jiang, N., Zhang, G., Pan, L., Yan, C., Zhang, L., Weng, Y., Wang, W., Chen, X., & Yang, G. (2017). Potential plasma lipid biomarkers in early-stage breast cancer. Biotechnology Letters, 39(11), 1657–1666.CrossRefPubMed Jiang, N., Zhang, G., Pan, L., Yan, C., Zhang, L., Weng, Y., Wang, W., Chen, X., & Yang, G. (2017). Potential plasma lipid biomarkers in early-stage breast cancer. Biotechnology Letters, 39(11), 1657–1666.CrossRefPubMed

go back to reference Serhan, C. N., & Levy, B. D. (2018). Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators. The Journal of Clinical Investigation, 128, 2657–2669.CrossRefPubMed Serhan, C. N., & Levy, B. D. (2018). Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators. The Journal of Clinical Investigation, 128, 2657–2669.CrossRefPubMed

go back to reference Sulciner, M. L., Serhan, C. N., Gilligan, M. M., Mudge, D. K., Chang, J., Gartung, A., Lehner, K. A., Bielenberg, D. R., Schmidt, B., Dalli, J., Greene, E. R., Gus-Brautbar, Y., Piwowarski, J., Mammoto, T., Zurakowski, D., Perretti, M., Sukhatme, V. P., Kaipainen, A., Kieran, M. W., Huang, S., & Panigrahy, D. (2018). Resolvins suppress tumor growth and enhance cancer therapy. The Journal of Experimental Medicine, 215(1), 115–140.PubMedCentralCrossRefPubMed Sulciner, M. L., Serhan, C. N., Gilligan, M. M., Mudge, D. K., Chang, J., Gartung, A., Lehner, K. A., Bielenberg, D. R., Schmidt, B., Dalli, J., Greene, E. R., Gus-Brautbar, Y., Piwowarski, J., Mammoto, T., Zurakowski, D., Perretti, M., Sukhatme, V. P., Kaipainen, A., Kieran, M. W., Huang, S., & Panigrahy, D. (2018). Resolvins suppress tumor growth and enhance cancer therapy. The Journal of Experimental Medicine, 215(1), 115–140.PubMedCentralCrossRefPubMed

go back to reference Burr, G. O., & Burr, M. M. (1973). Nutrition classics from The Journal of Biological Chemistry 82:345-67, 1929. A new deficiency disease produced by the rigid exclusion of fat from the diet. Nutrition Reviews, 31(8), 248–249.PubMed Burr, G. O., & Burr, M. M. (1973). Nutrition classics from The Journal of Biological Chemistry 82:345-67, 1929. A new deficiency disease produced by the rigid exclusion of fat from the diet. Nutrition Reviews, 31(8), 248–249.PubMed

go back to reference Nohturfft, A., & Zhang, S. C. (2009). Coordination of lipid metabolism in membrane biogenesis. Annual Review of Cell and Developmental Biology, 25, 539–566.CrossRefPubMed Nohturfft, A., & Zhang, S. C. (2009). Coordination of lipid metabolism in membrane biogenesis. Annual Review of Cell and Developmental Biology, 25, 539–566.CrossRefPubMed

go back to reference Singer, S. J., & Nicolson, G. L. (1972). The fluid mosaic model of the structure of cell membranes. Science, 175(4023), 720–731.CrossRefPubMed Singer, S. J., & Nicolson, G. L. (1972). The fluid mosaic model of the structure of cell membranes. Science, 175(4023), 720–731.CrossRefPubMed

go back to reference Dolce, V., Rita Cappello, A., Lappano, R., & Maggiolini, M. (2011). Glycerophospholipid synthesis as a novel drug target against cancer. Current Molecular Pharmacology, 4(3), 167–175.CrossRefPubMed Dolce, V., Rita Cappello, A., Lappano, R., & Maggiolini, M. (2011). Glycerophospholipid synthesis as a novel drug target against cancer. Current Molecular Pharmacology, 4(3), 167–175.CrossRefPubMed

go back to reference Williams, C. D., Whitley, B. M., Hoyo, C., Grant, D. J., Iraggi, J. D., Newman, K. A., Gerber, L., Taylor, L. A., McKeever, M. G., & Freedland, S. J. (2011). A high ratio of dietary n-6/n-3 polyunsaturated fatty acids is associated with increased risk of prostate cancer. Nutrition Research, 31(1), 1–8.CrossRefPubMed Williams, C. D., Whitley, B. M., Hoyo, C., Grant, D. J., Iraggi, J. D., Newman, K. A., Gerber, L., Taylor, L. A., McKeever, M. G., & Freedland, S. J. (2011). A high ratio of dietary n-6/n-3 polyunsaturated fatty acids is associated with increased risk of prostate cancer. Nutrition Research, 31(1), 1–8.CrossRefPubMed

go back to reference Apte, S. A., Cavazos, D. A., Whelan, K. A., & deGraffenried, L. A. (2013). A low dietary ratio of omega-6 to omega-3 fatty acids may delay progression of prostate cancer. Nutrition and Cancer, 65(4), 556–562.CrossRefPubMed Apte, S. A., Cavazos, D. A., Whelan, K. A., & deGraffenried, L. A. (2013). A low dietary ratio of omega-6 to omega-3 fatty acids may delay progression of prostate cancer. Nutrition and Cancer, 65(4), 556–562.CrossRefPubMed

go back to reference Pan, J., Cheng, L., Bi, X., Zhang, X., Liu, S., Bai, X., Li, F., & Zhao, A. Z. (2015). Elevation of omega-3 polyunsaturated fatty acids attenuates PTEN-deficiency induced endometrial cancer development through regulation of COX-2 and PGE2 production. Scientific Reports, 5, 14958.PubMedCentralCrossRefPubMed Pan, J., Cheng, L., Bi, X., Zhang, X., Liu, S., Bai, X., Li, F., & Zhao, A. Z. (2015). Elevation of omega-3 polyunsaturated fatty acids attenuates PTEN-deficiency induced endometrial cancer development through regulation of COX-2 and PGE2 production. Scientific Reports, 5, 14958.PubMedCentralCrossRefPubMed

go back to reference Brasky, T. M., Darke, A. K., Song, X., Tangen, C. M., Goodman, P. J., Thompson, I. M., Meyskens Jr., F. L., Goodman, G. E., Minasian, L. M., Parnes, H. L., Klein, E. A., & Kristal, A. R. (2013). Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. Journal of the National Cancer Institute, 105(15), 1132–1141.PubMedCentralCrossRefPubMed Brasky, T. M., Darke, A. K., Song, X., Tangen, C. M., Goodman, P. J., Thompson, I. M., Meyskens Jr., F. L., Goodman, G. E., Minasian, L. M., Parnes, H. L., Klein, E. A., & Kristal, A. R. (2013). Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. Journal of the National Cancer Institute, 105(15), 1132–1141.PubMedCentralCrossRefPubMed

go back to reference Zhang, J., Zhang, L., Ye, X., Chen, L., Zhang, L., Gao, Y., Kang, J. X., & Cai, C. (2013). Characteristics of fatty acid distribution is associated with colorectal cancer prognosis. Prostaglandins, Leukotrienes, and Essential Fatty Acids, 88(5), 355–360.CrossRefPubMed Zhang, J., Zhang, L., Ye, X., Chen, L., Zhang, L., Gao, Y., Kang, J. X., & Cai, C. (2013). Characteristics of fatty acid distribution is associated with colorectal cancer prognosis. Prostaglandins, Leukotrienes, and Essential Fatty Acids, 88(5), 355–360.CrossRefPubMed

go back to reference von Euler, U. S. (1936). On the specific vaso-dilating and plain muscle stimulating substances from accessory genital glands in man and certain animals (prostaglandin and vesiglandin). The Journal of Physiology, 88(2), 213–234.CrossRef von Euler, U. S. (1936). On the specific vaso-dilating and plain muscle stimulating substances from accessory genital glands in man and certain animals (prostaglandin and vesiglandin). The Journal of Physiology, 88(2), 213–234.CrossRef

go back to reference Samuelsson, B. (1983). From studies of biochemical mechanism to novel biological mediators: prostaglandin endoperoxides, thromboxanes, and leukotrienes. Nobel Lecture, 8 December 1982. Bioscience Reports, 3(9), 791–813.CrossRefPubMed Samuelsson, B. (1983). From studies of biochemical mechanism to novel biological mediators: prostaglandin endoperoxides, thromboxanes, and leukotrienes. Nobel Lecture, 8 December 1982. Bioscience Reports, 3(9), 791–813.CrossRefPubMed

go back to reference Corey, E. J., Andersen, N. H., Carlson, R. M., Paust, J., Vedejs, E., Vlattas, I., & Winter, R. E. K. (1968). Total synthesis of prostaglandins. Synthesis of the pure dl-E1, -F1-alpha-F1-beta, -A1, and -B1 hormones. Journal of the American Chemical Society, 90(12), 3245–3247.CrossRefPubMed Corey, E. J., Andersen, N. H., Carlson, R. M., Paust, J., Vedejs, E., Vlattas, I., & Winter, R. E. K. (1968). Total synthesis of prostaglandins. Synthesis of the pure dl-E1, -F1-alpha-F1-beta, -A1, and -B1 hormones. Journal of the American Chemical Society, 90(12), 3245–3247.CrossRefPubMed

go back to reference Corey, E. J., Vlattas, I., Andersen, N. H., & Harding, K. (1968). A new total synthesis of prostaglandins of the E1 and F1 series including 11-epiprostaglandins. Journal of the American Chemical Society, 90(12), 3247–3248.CrossRefPubMed Corey, E. J., Vlattas, I., Andersen, N. H., & Harding, K. (1968). A new total synthesis of prostaglandins of the E1 and F1 series including 11-epiprostaglandins. Journal of the American Chemical Society, 90(12), 3247–3248.CrossRefPubMed

go back to reference Tashjian Jr., A. H., et al. (1975). Hydrocortisone inhibits prostaglandin production by mouse fibrosarcoma cells. Nature, 258(5537), 739–741.CrossRefPubMed Tashjian Jr., A. H., et al. (1975). Hydrocortisone inhibits prostaglandin production by mouse fibrosarcoma cells. Nature, 258(5537), 739–741.CrossRefPubMed

go back to reference Levine, L., Hinkle, P. M., Voelkel, E. F., & Tashjian Jr., A. H. (1972). Prostaglandin production by mouse fibrosarcoma cells in culture: inhibition by indomethacin and aspirin. Biochemical and Biophysical Research Communications, 47(4), 888–896.CrossRefPubMed Levine, L., Hinkle, P. M., Voelkel, E. F., & Tashjian Jr., A. H. (1972). Prostaglandin production by mouse fibrosarcoma cells in culture: inhibition by indomethacin and aspirin. Biochemical and Biophysical Research Communications, 47(4), 888–896.CrossRefPubMed

go back to reference Klein, D. C., & Raisz, L. G. (1970). Prostaglandins: stimulation of bone resorption in tissue culture. Endocrinology, 86(6), 1436–1440.CrossRefPubMed Klein, D. C., & Raisz, L. G. (1970). Prostaglandins: stimulation of bone resorption in tissue culture. Endocrinology, 86(6), 1436–1440.CrossRefPubMed

go back to reference Tashjian Jr., A. H., Voelkel, E. F., Goldhaber, P., & Levine, L. (1973). Successful treatment of hypercalcemia by indomethacin in mice bearing a prostaglandin-producing fibrosarcoma. Prostaglandins, 3(4), 515–524.CrossRefPubMed Tashjian Jr., A. H., Voelkel, E. F., Goldhaber, P., & Levine, L. (1973). Successful treatment of hypercalcemia by indomethacin in mice bearing a prostaglandin-producing fibrosarcoma. Prostaglandins, 3(4), 515–524.CrossRefPubMed

go back to reference Tashjian Jr., A. H. (1978). Role of prostaglandins in the production of hypercalcemia by tumors. Cancer Research, 38(11 Pt 2), 4138–4141.PubMed Tashjian Jr., A. H. (1978). Role of prostaglandins in the production of hypercalcemia by tumors. Cancer Research, 38(11 Pt 2), 4138–4141.PubMed

go back to reference Vane, J. R. (1971). Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature: New Biology, 231(25), 232–235. Vane, J. R. (1971). Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature: New Biology, 231(25), 232–235.

go back to reference Crofford, L. J. (1997). COX-1 and COX-2 tissue expression: implications and predictions. The Journal of Rheumatology. Supplement, 49, 15–19.PubMed Crofford, L. J. (1997). COX-1 and COX-2 tissue expression: implications and predictions. The Journal of Rheumatology. Supplement, 49, 15–19.PubMed

go back to reference Hagen, A. A., White, R. P., & Robertson, J. T. (1979). Synthesis of prostaglandins and thromboxane B2 by cerebral arteries. Stroke, 10(3), 306–309.CrossRefPubMed Hagen, A. A., White, R. P., & Robertson, J. T. (1979). Synthesis of prostaglandins and thromboxane B2 by cerebral arteries. Stroke, 10(3), 306–309.CrossRefPubMed

go back to reference Eberhart, C. E., Coffey, R. J., Radhika, A., Giardiello, F. M., Ferrenbach, S., & Dubois, R. N. (1994). Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology, 107(4), 1183–1188.CrossRefPubMed Eberhart, C. E., Coffey, R. J., Radhika, A., Giardiello, F. M., Ferrenbach, S., & Dubois, R. N. (1994). Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology, 107(4), 1183–1188.CrossRefPubMed

go back to reference Steinbach, G., Lynch, P. M., Phillips, R. K. S., Wallace, M. H., Hawk, E., Gordon, G. B., Wakabayashi, N., Saunders, B., Shen, Y., Fujimura, T., Su, L. K., Levin, B., Godio, L., Patterson, S., Rodriguez-Bigas, M. A., Jester, S. L., King, K. L., Schumacher, M., Abbruzzese, J., DuBois, R. N., Hittelman, W. N., Zimmerman, S., Sherman, J. W., & Kelloff, G. (2000). The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. The New England Journal of Medicine, 342(26), 1946–1952.CrossRefPubMed Steinbach, G., Lynch, P. M., Phillips, R. K. S., Wallace, M. H., Hawk, E., Gordon, G. B., Wakabayashi, N., Saunders, B., Shen, Y., Fujimura, T., Su, L. K., Levin, B., Godio, L., Patterson, S., Rodriguez-Bigas, M. A., Jester, S. L., King, K. L., Schumacher, M., Abbruzzese, J., DuBois, R. N., Hittelman, W. N., Zimmerman, S., Sherman, J. W., & Kelloff, G. (2000). The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. The New England Journal of Medicine, 342(26), 1946–1952.CrossRefPubMed

go back to reference Wang, D., & DuBois, R. N. (2018). Role of prostanoids in gastrointestinal cancer. The Journal of Clinical Investigation, 128, 2732–2742.CrossRefPubMed Wang, D., & DuBois, R. N. (2018). Role of prostanoids in gastrointestinal cancer. The Journal of Clinical Investigation, 128, 2732–2742.CrossRefPubMed

go back to reference Xu, X. C. (2002). COX-2 inhibitors in cancer treatment and prevention, a recent development. Anti-Cancer Drugs, 13(2), 127–137.CrossRefPubMed Xu, X. C. (2002). COX-2 inhibitors in cancer treatment and prevention, a recent development. Anti-Cancer Drugs, 13(2), 127–137.CrossRefPubMed

go back to reference Wang, D., & Dubois, R. N. (2006). Prostaglandins and cancer. Gut, 55(1), 115–122.PubMedCentralCrossRefPubMed Wang, D., & Dubois, R. N. (2006). Prostaglandins and cancer. Gut, 55(1), 115–122.PubMedCentralCrossRefPubMed

go back to reference Bennett, A., Tacca, M. D., Stamford, I. F., & Zebro, T. (1977). Prostaglandins from tumours of human large bowel. British Journal of Cancer, 35(6), 881–884.PubMedCentralCrossRefPubMed Bennett, A., Tacca, M. D., Stamford, I. F., & Zebro, T. (1977). Prostaglandins from tumours of human large bowel. British Journal of Cancer, 35(6), 881–884.PubMedCentralCrossRefPubMed

go back to reference Bennett, A., Charlier, E. M., McDonald, A., Simpson, J. S., Stamford, I. F., & Zebro, T. (1977). Prostaglandins and breast cancer. Lancet, 2(8039), 624–626.CrossRefPubMed Bennett, A., Charlier, E. M., McDonald, A., Simpson, J. S., Stamford, I. F., & Zebro, T. (1977). Prostaglandins and breast cancer. Lancet, 2(8039), 624–626.CrossRefPubMed

go back to reference Harris, R. E., Chlebowski, R. T., Jackson, R. D., Frid, D. J., Ascenseo, J. L., Anderson, G., Loar, A., Rodabough, R. J., White, E., McTiernan, A., & Women’s Health Initiative. (2003). Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women’s Health Initiative. Cancer Research, 63(18), 6096–6101.PubMed Harris, R. E., Chlebowski, R. T., Jackson, R. D., Frid, D. J., Ascenseo, J. L., Anderson, G., Loar, A., Rodabough, R. J., White, E., McTiernan, A., & Women’s Health Initiative. (2003). Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women’s Health Initiative. Cancer Research, 63(18), 6096–6101.PubMed

go back to reference Reddy, B. S., Hirose, Y., Lubet, R., Steele, V., Kelloff, G., Paulson, S., Seibert, K., & Rao, C. V. (2000). Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Research, 60(2), 293–297.PubMed Reddy, B. S., Hirose, Y., Lubet, R., Steele, V., Kelloff, G., Paulson, S., Seibert, K., & Rao, C. V. (2000). Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Research, 60(2), 293–297.PubMed

go back to reference Thun, M. J., Namboodiri, M. M., & Heath Jr., C. W. (1991). Aspirin use and reduced risk of fatal colon cancer. The New England Journal of Medicine, 325(23), 1593–1596.CrossRefPubMed Thun, M. J., Namboodiri, M. M., & Heath Jr., C. W. (1991). Aspirin use and reduced risk of fatal colon cancer. The New England Journal of Medicine, 325(23), 1593–1596.CrossRefPubMed

go back to reference Waddell, W. R., & Loughry, R. W. (1983). Sulindac for polyposis of the colon. Journal of Surgical Oncology, 24(1), 83–87.CrossRefPubMed Waddell, W. R., & Loughry, R. W. (1983). Sulindac for polyposis of the colon. Journal of Surgical Oncology, 24(1), 83–87.CrossRefPubMed

go back to reference Whelton, A., & Hamilton, C. W. (1991). Nonsteroidal anti-inflammatory drugs: effects on kidney function. Journal of Clinical Pharmacology, 31(7), 588–598.CrossRefPubMed Whelton, A., & Hamilton, C. W. (1991). Nonsteroidal anti-inflammatory drugs: effects on kidney function. Journal of Clinical Pharmacology, 31(7), 588–598.CrossRefPubMed

go back to reference Kearney, P. M., Baigent, C., Godwin, J., Halls, H., Emberson, J. R., & Patrono, C. (2006). Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ, 332(7553), 1302–1308.PubMedCentralCrossRefPubMed Kearney, P. M., Baigent, C., Godwin, J., Halls, H., Emberson, J. R., & Patrono, C. (2006). Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ, 332(7553), 1302–1308.PubMedCentralCrossRefPubMed

go back to reference MacDonald, T. M., Morant, S. V., Robinson, G. C., Shield, M. J., McGilchrist, M. M., Murray, F. E., & McDevitt, D. G. (1997). Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study. BMJ, 315(7119), 1333–1337.PubMedCentralCrossRefPubMed MacDonald, T. M., Morant, S. V., Robinson, G. C., Shield, M. J., McGilchrist, M. M., Murray, F. E., & McDevitt, D. G. (1997). Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study. BMJ, 315(7119), 1333–1337.PubMedCentralCrossRefPubMed

go back to reference Solomon, S. D., Pfeffer, M. A., McMurray, J. J. V., Fowler, R., Finn, P., Levin, B., Eagle, C., Hawk, E., Lechuga, M., Zauber, A. G., Bertagnolli, M. M., Arber, N., Wittes, J., & for the APC and PreSAP Trial Investigators. (2006). Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation, 114(10), 1028–1035.CrossRefPubMed Solomon, S. D., Pfeffer, M. A., McMurray, J. J. V., Fowler, R., Finn, P., Levin, B., Eagle, C., Hawk, E., Lechuga, M., Zauber, A. G., Bertagnolli, M. M., Arber, N., Wittes, J., & for the APC and PreSAP Trial Investigators. (2006). Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation, 114(10), 1028–1035.CrossRefPubMed

go back to reference Graham, D. J., et al. (2005). Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet, 365(9458), 475–481.CrossRefPubMed Graham, D. J., et al. (2005). Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet, 365(9458), 475–481.CrossRefPubMed

go back to reference Couzin, J. (2004). Drug safety. Withdrawal of Vioxx casts a shadow over COX-2 inhibitors. Science, 306(5695), 384–385.CrossRefPubMed Couzin, J. (2004). Drug safety. Withdrawal of Vioxx casts a shadow over COX-2 inhibitors. Science, 306(5695), 384–385.CrossRefPubMed

go back to reference Gomes, R. N., & Colquhoun, A. (2012). E series prostaglandins alter the proliferative, apoptotic and migratory properties of T98G human glioma cells in vitro. Lipids in Health and Disease, 11, 171.PubMedCentralCrossRefPubMed Gomes, R. N., & Colquhoun, A. (2012). E series prostaglandins alter the proliferative, apoptotic and migratory properties of T98G human glioma cells in vitro. Lipids in Health and Disease, 11, 171.PubMedCentralCrossRefPubMed

go back to reference Venza, I., Visalli, M., Fortunato, C., Ruggeri, M., Ratone, S., Caffo, M., Caruso, G., Alafaci, C., Tomasello, F., Teti, D., & Venza, M. (2012). PGE2 induces interleukin-8 derepression in human astrocytoma through coordinated DNA demethylation and histone hyperacetylation. Epigenetics, 7(11), 1315–1330.PubMedCentralCrossRefPubMed Venza, I., Visalli, M., Fortunato, C., Ruggeri, M., Ratone, S., Caffo, M., Caruso, G., Alafaci, C., Tomasello, F., Teti, D., & Venza, M. (2012). PGE2 induces interleukin-8 derepression in human astrocytoma through coordinated DNA demethylation and histone hyperacetylation. Epigenetics, 7(11), 1315–1330.PubMedCentralCrossRefPubMed

go back to reference Larsson, K., Kock, A., Idborg, H., Arsenian Henriksson, M., Martinsson, T., Johnsen, J. I., Korotkova, M., Kogner, P., & Jakobsson, P. J. (2015). COX/mPGES-1/PGE2 pathway depicts an inflammatory-dependent high-risk neuroblastoma subset. Proceedings of the National Academy of Sciences of the United States of America, 112(26), 8070–8075.PubMedCentralCrossRefPubMed Larsson, K., Kock, A., Idborg, H., Arsenian Henriksson, M., Martinsson, T., Johnsen, J. I., Korotkova, M., Kogner, P., & Jakobsson, P. J. (2015). COX/mPGES-1/PGE2 pathway depicts an inflammatory-dependent high-risk neuroblastoma subset. Proceedings of the National Academy of Sciences of the United States of America, 112(26), 8070–8075.PubMedCentralCrossRefPubMed

go back to reference Li, H. J., Reinhardt, F., Herschman, H. R., & Weinberg, R. A. (2012). Cancer-stimulated mesenchymal stem cells create a carcinoma stem cell niche via prostaglandin E2 signaling. Cancer Discovery, 2(9), 840–855.CrossRefPubMed Li, H. J., Reinhardt, F., Herschman, H. R., & Weinberg, R. A. (2012). Cancer-stimulated mesenchymal stem cells create a carcinoma stem cell niche via prostaglandin E2 signaling. Cancer Discovery, 2(9), 840–855.CrossRefPubMed

go back to reference Van Scott, E. J., & Reinertson, R. P. (1961). The modulating influence of stromal environment on epithelial cells studied in human autotransplants. The Journal of Investigative Dermatology, 36, 109–131.CrossRef Van Scott, E. J., & Reinertson, R. P. (1961). The modulating influence of stromal environment on epithelial cells studied in human autotransplants. The Journal of Investigative Dermatology, 36, 109–131.CrossRef

go back to reference Zhang, A., Wang, M. H., Dong, Z., & Yang, T. (2006). Prostaglandin E2 is a potent inhibitor of epithelial-to-mesenchymal transition: interaction with hepatocyte growth factor. American Journal of Physiology. Renal Physiology, 291(6), F1323–F1331.CrossRefPubMed Zhang, A., Wang, M. H., Dong, Z., & Yang, T. (2006). Prostaglandin E2 is a potent inhibitor of epithelial-to-mesenchymal transition: interaction with hepatocyte growth factor. American Journal of Physiology. Renal Physiology, 291(6), F1323–F1331.CrossRefPubMed

go back to reference Fidler, I. J. (2003). The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nature Reviews. Cancer, 3(6), 453–458.CrossRefPubMed Fidler, I. J. (2003). The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nature Reviews. Cancer, 3(6), 453–458.CrossRefPubMed

go back to reference Karnezis, T., Shayan, R., Caesar, C., Roufail, S., Harris, N. C., Ardipradja, K., Zhang, Y. F., Williams, S. P., Farnsworth, R. H., Chai, M. G., Rupasinghe, T. W. T., Tull, D. L., Baldwin, M. E., Sloan, E. K., Fox, S. B., Achen, M. G., & Stacker, S. A. (2012). VEGF-D promotes tumor metastasis by regulating prostaglandins produced by the collecting lymphatic endothelium. Cancer Cell, 21(2), 181–195.CrossRefPubMed Karnezis, T., Shayan, R., Caesar, C., Roufail, S., Harris, N. C., Ardipradja, K., Zhang, Y. F., Williams, S. P., Farnsworth, R. H., Chai, M. G., Rupasinghe, T. W. T., Tull, D. L., Baldwin, M. E., Sloan, E. K., Fox, S. B., Achen, M. G., & Stacker, S. A. (2012). VEGF-D promotes tumor metastasis by regulating prostaglandins produced by the collecting lymphatic endothelium. Cancer Cell, 21(2), 181–195.CrossRefPubMed

go back to reference Wu, J., Zhang, Y., Frilot, N., Kim, J. I., Kim, W. J., & Daaka, Y. (2011). Prostaglandin E2 regulates renal cell carcinoma invasion through the EP4 receptor-Rap GTPase signal transduction pathway. The Journal of Biological Chemistry, 286(39), 33954–33962.PubMedCentralCrossRefPubMed Wu, J., Zhang, Y., Frilot, N., Kim, J. I., Kim, W. J., & Daaka, Y. (2011). Prostaglandin E2 regulates renal cell carcinoma invasion through the EP4 receptor-Rap GTPase signal transduction pathway. The Journal of Biological Chemistry, 286(39), 33954–33962.PubMedCentralCrossRefPubMed

go back to reference Li, Z., Zhang, Y., Kim, W. J., & Daaka, Y. (2013). PGE2 promotes renal carcinoma cell invasion through activated RalA. Oncogene, 32(11), 1408–1415.CrossRefPubMed Li, Z., Zhang, Y., Kim, W. J., & Daaka, Y. (2013). PGE2 promotes renal carcinoma cell invasion through activated RalA. Oncogene, 32(11), 1408–1415.CrossRefPubMed

go back to reference Wang, D., Fu, L., Sun, H., Guo, L., & DuBois, R. N. (2015). Prostaglandin E2 promotes colorectal cancer stem cell expansion and metastasis in mice. Gastroenterology, 149(7), 1884–1895 e4.PubMedCentralCrossRefPubMed Wang, D., Fu, L., Sun, H., Guo, L., & DuBois, R. N. (2015). Prostaglandin E2 promotes colorectal cancer stem cell expansion and metastasis in mice. Gastroenterology, 149(7), 1884–1895 e4.PubMedCentralCrossRefPubMed

go back to reference Kurtova, A. V., Xiao, J., Mo, Q., Pazhanisamy, S., Krasnow, R., Lerner, S. P., Chen, F., Roh, T. T., Lay, E., Ho, P. L., & Chan, K. S. (2015). Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance. Nature, 517(7533), 209–213.CrossRefPubMed Kurtova, A. V., Xiao, J., Mo, Q., Pazhanisamy, S., Krasnow, R., Lerner, S. P., Chen, F., Roh, T. T., Lay, E., Ho, P. L., & Chan, K. S. (2015). Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance. Nature, 517(7533), 209–213.CrossRefPubMed

go back to reference Lewis, R. A., & Austen, K. F. (1981). Mediation of local homeostasis and inflammation by leukotrienes and other mast cell-dependent compounds. Nature, 293(5828), 103–108.CrossRefPubMed Lewis, R. A., & Austen, K. F. (1981). Mediation of local homeostasis and inflammation by leukotrienes and other mast cell-dependent compounds. Nature, 293(5828), 103–108.CrossRefPubMed

go back to reference Lewis, R. A., et al. (1982). Prostaglandin D2 generation after activation of rat and human mast cells with anti-IgE. Journal of Immunology, 129(4), 1627–1631. Lewis, R. A., et al. (1982). Prostaglandin D2 generation after activation of rat and human mast cells with anti-IgE. Journal of Immunology, 129(4), 1627–1631.

go back to reference Murata, T., Aritake, K., Matsumoto, S., Kamauchi, S., Nakagawa, T., Hori, M., Momotani, E., Urade, Y., & Ozaki, H. (2011). Prostagladin D2 is a mast cell-derived antiangiogenic factor in lung carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 108(49), 19802–19807.PubMedCentralCrossRefPubMed Murata, T., Aritake, K., Matsumoto, S., Kamauchi, S., Nakagawa, T., Hori, M., Momotani, E., Urade, Y., & Ozaki, H. (2011). Prostagladin D2 is a mast cell-derived antiangiogenic factor in lung carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 108(49), 19802–19807.PubMedCentralCrossRefPubMed

go back to reference Kliewer, S. A., Lenhard, J. M., Willson, T. M., Patel, I., Morris, D. C., & Lehmann, J. M. (1995). A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell, 83(5), 813–819.CrossRefPubMed Kliewer, S. A., Lenhard, J. M., Willson, T. M., Patel, I., Morris, D. C., & Lehmann, J. M. (1995). A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell, 83(5), 813–819.CrossRefPubMed

go back to reference Fujita, M., Tohji, C., Honda, Y., Yamamoto, Y., Nakamura, T., Yagami, T., Yamamori, M., & Okamura, N. (2012). Cytotoxicity of 15-deoxy-Delta(12,14)-prostaglandin J(2) through PPARgamma-independent pathway and the involvement of the JNK and Akt pathway in renal cell carcinoma. International Journal of Medical Sciences, 9(7), 555–566.PubMedCentralCrossRefPubMed Fujita, M., Tohji, C., Honda, Y., Yamamoto, Y., Nakamura, T., Yagami, T., Yamamori, M., & Okamura, N. (2012). Cytotoxicity of 15-deoxy-Delta(12,14)-prostaglandin J(2) through PPARgamma-independent pathway and the involvement of the JNK and Akt pathway in renal cell carcinoma. International Journal of Medical Sciences, 9(7), 555–566.PubMedCentralCrossRefPubMed

go back to reference Hashimoto, K., Ethridge, R. T., & Evers, B. M. (2002). Peroxisome proliferator-activated receptor gamma ligand inhibits cell growth and invasion of human pancreatic cancer cells. International Journal of Gastrointestinal Cancer, 32(1), 7–22.CrossRefPubMed Hashimoto, K., Ethridge, R. T., & Evers, B. M. (2002). Peroxisome proliferator-activated receptor gamma ligand inhibits cell growth and invasion of human pancreatic cancer cells. International Journal of Gastrointestinal Cancer, 32(1), 7–22.CrossRefPubMed

go back to reference Emi, M., & Maeyama, K. (2004). The biphasic effects of cyclopentenone prostaglandins, prostaglandin J(2) and 15-deoxy-Delta(12,14)-prostaglandin J(2) on proliferation and apoptosis in rat basophilic leukemia (RBL-2H3) cells. Biochemical Pharmacology, 67(7), 1259–1267.CrossRefPubMed Emi, M., & Maeyama, K. (2004). The biphasic effects of cyclopentenone prostaglandins, prostaglandin J(2) and 15-deoxy-Delta(12,14)-prostaglandin J(2) on proliferation and apoptosis in rat basophilic leukemia (RBL-2H3) cells. Biochemical Pharmacology, 67(7), 1259–1267.CrossRefPubMed

go back to reference Han, H., Shin, S. W., Seo, C. Y., Kwon, H. C., Han, J. Y., Kim, I. H., Kwak, J. Y., & Park, J. I. (2007). 15-Deoxy-delta 12,14-prostaglandin J2 (15d-PGJ 2) sensitizes human leukemic HL-60 cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through Akt downregulation. Apoptosis, 12(11), 2101–2114.CrossRefPubMed Han, H., Shin, S. W., Seo, C. Y., Kwon, H. C., Han, J. Y., Kim, I. H., Kwak, J. Y., & Park, J. I. (2007). 15-Deoxy-delta 12,14-prostaglandin J2 (15d-PGJ 2) sensitizes human leukemic HL-60 cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through Akt downregulation. Apoptosis, 12(11), 2101–2114.CrossRefPubMed

go back to reference Murata, T., Ushikubi, F., Matsuoka, T., Hirata, M., Yamasaki, A., Sugimoto, Y., Ichikawa, A., Aze, Y., Tanaka, T., Yoshida, N., Ueno, A., Oh-ishi, S., & Narumiya, S. (1997). Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature, 388(6643), 678–682.CrossRefPubMed Murata, T., Ushikubi, F., Matsuoka, T., Hirata, M., Yamasaki, A., Sugimoto, Y., Ichikawa, A., Aze, Y., Tanaka, T., Yoshida, N., Ueno, A., Oh-ishi, S., & Narumiya, S. (1997). Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature, 388(6643), 678–682.CrossRefPubMed

go back to reference Komhoff, M., et al. (1998). Localization of the prostacyclin receptor in human kidney. Kidney International, 54(6), 1899–1908.CrossRefPubMed Komhoff, M., et al. (1998). Localization of the prostacyclin receptor in human kidney. Kidney International, 54(6), 1899–1908.CrossRefPubMed

go back to reference Brock, T. G., McNish, R. W., & Peters-Golden, M. (1999). Arachidonic acid is preferentially metabolized by cyclooxygenase-2 to prostacyclin and prostaglandin E2. The Journal of Biological Chemistry, 274(17), 11660–11666.CrossRefPubMed Brock, T. G., McNish, R. W., & Peters-Golden, M. (1999). Arachidonic acid is preferentially metabolized by cyclooxygenase-2 to prostacyclin and prostaglandin E2. The Journal of Biological Chemistry, 274(17), 11660–11666.CrossRefPubMed

go back to reference Lim, H., Gupta, R. A., Ma, W. G., Paria, B. C., Moller, D. E., Morrow, J. D., DuBois, R. N., Trzaskos, J. M., & Dey, S. K. (1999). Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARdelta. Genes & Development, 13(12), 1561–1574.CrossRef Lim, H., Gupta, R. A., Ma, W. G., Paria, B. C., Moller, D. E., Morrow, J. D., DuBois, R. N., Trzaskos, J. M., & Dey, S. K. (1999). Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARdelta. Genes & Development, 13(12), 1561–1574.CrossRef

go back to reference Forman, B. M., Chen, J., & Evans, R. M. (1997). Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proceedings of the National Academy of Sciences of the United States of America, 94(9), 4312–4317.PubMedCentralCrossRefPubMed Forman, B. M., Chen, J., & Evans, R. M. (1997). Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proceedings of the National Academy of Sciences of the United States of America, 94(9), 4312–4317.PubMedCentralCrossRefPubMed

go back to reference Gupta, R. A., Tan, J., Krause, W. F., Geraci, M. W., Willson, T. M., Dey, S. K., & DuBois, R. N. (2000). Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proceedings of the National Academy of Sciences of the United States of America, 97(24), 13275–13280.PubMedCentralCrossRefPubMed Gupta, R. A., Tan, J., Krause, W. F., Geraci, M. W., Willson, T. M., Dey, S. K., & DuBois, R. N. (2000). Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proceedings of the National Academy of Sciences of the United States of America, 97(24), 13275–13280.PubMedCentralCrossRefPubMed

go back to reference Takayama, O., Yamamoto, H., Damdinsuren, B., Sugita, Y., Ngan, C. Y., Xu, X., Tsujino, T., Takemasa, I., Ikeda, M., Sekimoto, M., Matsuura, N., & Monden, M. (2006). Expression of PPARdelta in multistage carcinogenesis of the colorectum: implications of malignant cancer morphology. British Journal of Cancer, 95(7), 889–895.PubMedCentralCrossRefPubMed Takayama, O., Yamamoto, H., Damdinsuren, B., Sugita, Y., Ngan, C. Y., Xu, X., Tsujino, T., Takemasa, I., Ikeda, M., Sekimoto, M., Matsuura, N., & Monden, M. (2006). Expression of PPARdelta in multistage carcinogenesis of the colorectum: implications of malignant cancer morphology. British Journal of Cancer, 95(7), 889–895.PubMedCentralCrossRefPubMed

go back to reference Wu, K. K., & Liou, J. Y. (2009). Cyclooxygenase inhibitors induce colon cancer cell apoptosis via PPARdelta --> 14-3-3epsilon pathway. Methods in Molecular Biology, 512, 295–307.CrossRefPubMed Wu, K. K., & Liou, J. Y. (2009). Cyclooxygenase inhibitors induce colon cancer cell apoptosis via PPARdelta --> 14-3-3epsilon pathway. Methods in Molecular Biology, 512, 295–307.CrossRefPubMed

go back to reference Klein, T., et al. (2015). Expression of prostacyclin-synthase in human breast cancer: negative prognostic factor and protection against cell death in vitro. Mediators of Inflammation, 2015, 864136.PubMedCentralPubMed Klein, T., et al. (2015). Expression of prostacyclin-synthase in human breast cancer: negative prognostic factor and protection against cell death in vitro. Mediators of Inflammation, 2015, 864136.PubMedCentralPubMed

go back to reference Camacho, M., Piñeiro, Z., Alcolea, S., García, J., Balart, J., Terra, X., Avilés-Jurado, F. X., Soler, M., Quer, M., León, X., & Vila, L. (2015). Prostacyclin-synthase expression in head and neck carcinoma patients and its prognostic value in the response to radiotherapy. The Journal of Pathology, 235(1), 125–135.CrossRefPubMed Camacho, M., Piñeiro, Z., Alcolea, S., García, J., Balart, J., Terra, X., Avilés-Jurado, F. X., Soler, M., Quer, M., León, X., & Vila, L. (2015). Prostacyclin-synthase expression in head and neck carcinoma patients and its prognostic value in the response to radiotherapy. The Journal of Pathology, 235(1), 125–135.CrossRefPubMed

go back to reference Li, T., Chen, Y., Zang, W., Geng, N., Ma, S., & Li, X. (2013). Prostacyclin and its analogues in pulmonary artery hypertension: a meta-analysis. Current Medical Research and Opinion, 29(8), 889–899.CrossRefPubMed Li, T., Chen, Y., Zang, W., Geng, N., Ma, S., & Li, X. (2013). Prostacyclin and its analogues in pulmonary artery hypertension: a meta-analysis. Current Medical Research and Opinion, 29(8), 889–899.CrossRefPubMed

go back to reference Sun, J., Zhang, J., Yan, W., Chen, C., Wu, G., Abbasi, S., Pham, B., Lee, S., Cheng, J., Memon, N. B., & Xi, Y. (2014). Iloprost prevents doxorubicin mediated human cardiac progenitor cell depletion. International Journal of Cardiology, 176(2), 536–539.CrossRefPubMed Sun, J., Zhang, J., Yan, W., Chen, C., Wu, G., Abbasi, S., Pham, B., Lee, S., Cheng, J., Memon, N. B., & Xi, Y. (2014). Iloprost prevents doxorubicin mediated human cardiac progenitor cell depletion. International Journal of Cardiology, 176(2), 536–539.CrossRefPubMed

go back to reference Keith, R. L., Karoor, V., Mozer, A. B., Hudish, T. M., le, M., & Miller, Y. E. (2010). Chemoprevention of murine lung cancer by gefitinib in combination with prostacyclin synthase overexpression. Lung Cancer, 70(1), 37–42.PubMedCentralCrossRefPubMed Keith, R. L., Karoor, V., Mozer, A. B., Hudish, T. M., le, M., & Miller, Y. E. (2010). Chemoprevention of murine lung cancer by gefitinib in combination with prostacyclin synthase overexpression. Lung Cancer, 70(1), 37–42.PubMedCentralCrossRefPubMed

go back to reference Osawa, T., Ohga, N., Hida, Y., Kitayama, K., Akiyama, K., Onodera, Y., Fujie, M., Shinohara, N., Shindoh, M., Nonomura, K., & Hida, K. (2012). Prostacyclin receptor in tumor endothelial cells promotes angiogenesis in an autocrine manner. Cancer Science, 103(6), 1038–1044.CrossRefPubMed Osawa, T., Ohga, N., Hida, Y., Kitayama, K., Akiyama, K., Onodera, Y., Fujie, M., Shinohara, N., Shindoh, M., Nonomura, K., & Hida, K. (2012). Prostacyclin receptor in tumor endothelial cells promotes angiogenesis in an autocrine manner. Cancer Science, 103(6), 1038–1044.CrossRefPubMed

go back to reference Knezevic, I., Borg, C., & Le Breton, G. C. (1993). Identification of Gq as one of the G-proteins which copurify with human platelet thromboxane A2/prostaglandin H2 receptors. The Journal of Biological Chemistry, 268(34), 26011–26017.PubMed Knezevic, I., Borg, C., & Le Breton, G. C. (1993). Identification of Gq as one of the G-proteins which copurify with human platelet thromboxane A2/prostaglandin H2 receptors. The Journal of Biological Chemistry, 268(34), 26011–26017.PubMed

go back to reference Hirata, M., Hayashi, Y., Ushikubi, F., Yokota, Y., Kageyama, R., Nakanishi, S., & Narumiya, S. (1991). Cloning and expression of cDNA for a human thromboxane A2 receptor. Nature, 349(6310), 617–620.CrossRefPubMed Hirata, M., Hayashi, Y., Ushikubi, F., Yokota, Y., Kageyama, R., Nakanishi, S., & Narumiya, S. (1991). Cloning and expression of cDNA for a human thromboxane A2 receptor. Nature, 349(6310), 617–620.CrossRefPubMed

go back to reference Ekambaram, P., Lambiv, W., Cazzolli, R., Ashton, A. W., & Honn, K. V. (2011). The thromboxane synthase and receptor signaling pathway in cancer: an emerging paradigm in cancer progression and metastasis. Cancer Metastasis Reviews, 30(3–4), 397–408.CrossRefPubMed Ekambaram, P., Lambiv, W., Cazzolli, R., Ashton, A. W., & Honn, K. V. (2011). The thromboxane synthase and receptor signaling pathway in cancer: an emerging paradigm in cancer progression and metastasis. Cancer Metastasis Reviews, 30(3–4), 397–408.CrossRefPubMed

go back to reference Huang, R. Y., Li, M. Y., Ng, C. S. H., Wan, I. Y. P., Kong, A. W. Y., du, J., Long, X., Underwood, M. J., Mok, T. S. K., & Chen, G. G. (2013). Thromboxane A2 receptor alpha promotes tumor growth through an autoregulatory feedback pathway. Journal of Molecular Cell Biology, 5(6), 380–390.CrossRefPubMed Huang, R. Y., Li, M. Y., Ng, C. S. H., Wan, I. Y. P., Kong, A. W. Y., du, J., Long, X., Underwood, M. J., Mok, T. S. K., & Chen, G. G. (2013). Thromboxane A2 receptor alpha promotes tumor growth through an autoregulatory feedback pathway. Journal of Molecular Cell Biology, 5(6), 380–390.CrossRefPubMed

go back to reference Huang, R. Y., Li, M. Y., Hsin, M. K. Y., Underwood, M. J., Ma, L. T., Mok, T. S. K., Warner, T. D., & Chen, G. G. (2011). 4-Methylnitrosamino-1-3-pyridyl-1-butanone (NNK) promotes lung cancer cell survival by stimulating thromboxane A2 and its receptor. Oncogene, 30(1), 106–116.CrossRefPubMed Huang, R. Y., Li, M. Y., Hsin, M. K. Y., Underwood, M. J., Ma, L. T., Mok, T. S. K., Warner, T. D., & Chen, G. G. (2011). 4-Methylnitrosamino-1-3-pyridyl-1-butanone (NNK) promotes lung cancer cell survival by stimulating thromboxane A2 and its receptor. Oncogene, 30(1), 106–116.CrossRefPubMed

go back to reference Li, X., & Tai, H. H. (2013). Activation of thromboxane A2 receptor (TP) increases the expression of monocyte chemoattractant protein-1 (MCP-1)/chemokine (C-C motif) ligand 2 (CCL2) and recruits macrophages to promote invasion of lung cancer cells. PLoS One, 8(1), e54073.PubMedCentralCrossRefPubMed Li, X., & Tai, H. H. (2013). Activation of thromboxane A2 receptor (TP) increases the expression of monocyte chemoattractant protein-1 (MCP-1)/chemokine (C-C motif) ligand 2 (CCL2) and recruits macrophages to promote invasion of lung cancer cells. PLoS One, 8(1), e54073.PubMedCentralCrossRefPubMed

go back to reference Matsui, Y., Amano, H., Ito, Y., Eshima, K., Suzuki, T., Ogawa, F., Iyoda, A., Satoh, Y., Kato, S., Nakamura, M., Kitasato, H., Narumiya, S., & Majima, M. (2012). Thromboxane A(2) receptor signaling facilitates tumor colonization through P-selectin-mediated interaction of tumor cells with platelets and endothelial cells. Cancer Science, 103(4), 700–707.CrossRefPubMed Matsui, Y., Amano, H., Ito, Y., Eshima, K., Suzuki, T., Ogawa, F., Iyoda, A., Satoh, Y., Kato, S., Nakamura, M., Kitasato, H., Narumiya, S., & Majima, M. (2012). Thromboxane A(2) receptor signaling facilitates tumor colonization through P-selectin-mediated interaction of tumor cells with platelets and endothelial cells. Cancer Science, 103(4), 700–707.CrossRefPubMed

go back to reference Shimizu, T. (2009). Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation. Annual Review of Pharmacology and Toxicology, 49, 123–150.CrossRefPubMed Shimizu, T. (2009). Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation. Annual Review of Pharmacology and Toxicology, 49, 123–150.CrossRefPubMed

go back to reference Yang, Y. J., Lee, S. H., Hong, S. J., & Chung, B. C. (1999). Comparison of fatty acid profiles in the serum of patients with prostate cancer and benign prostatic hyperplasia. Clinical Biochemistry, 32(6), 405–409.CrossRefPubMed Yang, Y. J., Lee, S. H., Hong, S. J., & Chung, B. C. (1999). Comparison of fatty acid profiles in the serum of patients with prostate cancer and benign prostatic hyperplasia. Clinical Biochemistry, 32(6), 405–409.CrossRefPubMed

go back to reference Chen, X., Chen, H., Dai, M., Ai, J., Li, Y., Mahon, B., Dai, S., & Deng, Y. (2016). Plasma lipidomics profiling identified lipid biomarkers in distinguishing early-stage breast cancer from benign lesions. Oncotarget, 7(24), 36622–36631.PubMedCentralPubMed Chen, X., Chen, H., Dai, M., Ai, J., Li, Y., Mahon, B., Dai, S., & Deng, Y. (2016). Plasma lipidomics profiling identified lipid biomarkers in distinguishing early-stage breast cancer from benign lesions. Oncotarget, 7(24), 36622–36631.PubMedCentralPubMed

go back to reference Morris, P. G., Zhou, X. K., Milne, G. L., Goldstein, D., Hawks, L. C., Dang, C. T., Modi, S., Fornier, M. N., Hudis, C. A., & Dannenberg, A. J. (2013). Increased levels of urinary PGE-M, a biomarker of inflammation, occur in association with obesity, aging, and lung metastases in patients with breast cancer. Cancer Prevention Research (Philadelphia, Pa.), 6(5), 428–436.CrossRef Morris, P. G., Zhou, X. K., Milne, G. L., Goldstein, D., Hawks, L. C., Dang, C. T., Modi, S., Fornier, M. N., Hudis, C. A., & Dannenberg, A. J. (2013). Increased levels of urinary PGE-M, a biomarker of inflammation, occur in association with obesity, aging, and lung metastases in patients with breast cancer. Cancer Prevention Research (Philadelphia, Pa.), 6(5), 428–436.CrossRef

go back to reference Kim, S., Taylor, J. A., Milne, G. L., & Sandler, D. P. (2013). Association between urinary prostaglandin E2 metabolite and breast cancer risk: a prospective, case-cohort study of postmenopausal women. Cancer Prevention Research (Philadelphia, Pa.), 6(6), 511–518.CrossRef Kim, S., Taylor, J. A., Milne, G. L., & Sandler, D. P. (2013). Association between urinary prostaglandin E2 metabolite and breast cancer risk: a prospective, case-cohort study of postmenopausal women. Cancer Prevention Research (Philadelphia, Pa.), 6(6), 511–518.CrossRef

go back to reference Ogretmen, B., & Hannun, Y. A. (2004). Biologically active sphingolipids in cancer pathogenesis and treatment. Nature Reviews. Cancer, 4(8), 604–616.CrossRefPubMed Ogretmen, B., & Hannun, Y. A. (2004). Biologically active sphingolipids in cancer pathogenesis and treatment. Nature Reviews. Cancer, 4(8), 604–616.CrossRefPubMed

go back to reference Nava, V. E., Cuvillier, O., Edsall, L. C., Kimura, K., Milstien, S., Gelmann, E. P., & Spiegel, S. (2000). Sphingosine enhances apoptosis of radiation-resistant prostate cancer cells. Cancer Research, 60(16), 4468–4474.PubMed Nava, V. E., Cuvillier, O., Edsall, L. C., Kimura, K., Milstien, S., Gelmann, E. P., & Spiegel, S. (2000). Sphingosine enhances apoptosis of radiation-resistant prostate cancer cells. Cancer Research, 60(16), 4468–4474.PubMed

go back to reference Lemonnier, L. A., Dillehay, D. L., Vespremi, M. J., Abrams, J., Brody, E., & Schmelz, E. M. (2003). Sphingomyelin in the suppression of colon tumors: prevention versus intervention. Archives of Biochemistry and Biophysics, 419(2), 129–138.CrossRefPubMed Lemonnier, L. A., Dillehay, D. L., Vespremi, M. J., Abrams, J., Brody, E., & Schmelz, E. M. (2003). Sphingomyelin in the suppression of colon tumors: prevention versus intervention. Archives of Biochemistry and Biophysics, 419(2), 129–138.CrossRefPubMed

go back to reference Chen, K., et al. (2014). DMS triggers apoptosis associated with the inhibition of SPHK1/NF-kappaB activation and increase in intracellular Ca2+ concentration in human cancer cells. International Journal of Molecular Medicine, 33(1), 17–24.CrossRefPubMed Chen, K., et al. (2014). DMS triggers apoptosis associated with the inhibition of SPHK1/NF-kappaB activation and increase in intracellular Ca2+ concentration in human cancer cells. International Journal of Molecular Medicine, 33(1), 17–24.CrossRefPubMed

go back to reference Meyers-Needham, M., Lewis, J. A., Gencer, S., Sentelle, R. D., Saddoughi, S. A., Clarke, C. J., Hannun, Y. A., Norell, H., da Palma, T. M., Nishimura, M., Kraveka, J. M., Khavandgar, Z., Murshed, M., Cevik, M. O., & Ogretmen, B. (2012). Off-target function of the Sonic hedgehog inhibitor cyclopamine in mediating apoptosis via nitric oxide-dependent neutral sphingomyelinase 2/ceramide induction. Molecular Cancer Therapeutics, 11(5), 1092–1102.PubMedCentralCrossRefPubMed Meyers-Needham, M., Lewis, J. A., Gencer, S., Sentelle, R. D., Saddoughi, S. A., Clarke, C. J., Hannun, Y. A., Norell, H., da Palma, T. M., Nishimura, M., Kraveka, J. M., Khavandgar, Z., Murshed, M., Cevik, M. O., & Ogretmen, B. (2012). Off-target function of the Sonic hedgehog inhibitor cyclopamine in mediating apoptosis via nitric oxide-dependent neutral sphingomyelinase 2/ceramide induction. Molecular Cancer Therapeutics, 11(5), 1092–1102.PubMedCentralCrossRefPubMed

go back to reference Bini, F., Frati, A., Garcia-Gil, M., Battistini, C., Granado, M., Martinesi, M., Mainardi, M., Vannini, E., Luzzati, F., Caleo, M., Peretto, P., Gomez-Muñoz, A., & Meacci, E. (2012). New signalling pathway involved in the anti-proliferative action of vitamin D(3) and its analogues in human neuroblastoma cells. A role for ceramide kinase. Neuropharmacology, 63(4), 524–537.CrossRefPubMed Bini, F., Frati, A., Garcia-Gil, M., Battistini, C., Granado, M., Martinesi, M., Mainardi, M., Vannini, E., Luzzati, F., Caleo, M., Peretto, P., Gomez-Muñoz, A., & Meacci, E. (2012). New signalling pathway involved in the anti-proliferative action of vitamin D(3) and its analogues in human neuroblastoma cells. A role for ceramide kinase. Neuropharmacology, 63(4), 524–537.CrossRefPubMed

go back to reference Kota, V., Szulc, Z. M., & Hama, H. (2012). Identification of C(6)-ceramide-interacting proteins in D6P2T Schwannoma cells. Proteomics, 12(13), 2179–2184.CrossRefPubMed Kota, V., Szulc, Z. M., & Hama, H. (2012). Identification of C(6)-ceramide-interacting proteins in D6P2T Schwannoma cells. Proteomics, 12(13), 2179–2184.CrossRefPubMed

go back to reference Sentelle, R. D., Senkal, C. E., Jiang, W., Ponnusamy, S., Gencer, S., Panneer Selvam, S., Ramshesh, V. K., Peterson, Y. K., Lemasters, J. J., Szulc, Z. M., Bielawski, J., & Ogretmen, B. (2012). Ceramide targets autophagosomes to mitochondria and induces lethal mitophagy. Nature Chemical Biology, 8(10), 831–838.PubMedCentralCrossRefPubMed Sentelle, R. D., Senkal, C. E., Jiang, W., Ponnusamy, S., Gencer, S., Panneer Selvam, S., Ramshesh, V. K., Peterson, Y. K., Lemasters, J. J., Szulc, Z. M., Bielawski, J., & Ogretmen, B. (2012). Ceramide targets autophagosomes to mitochondria and induces lethal mitophagy. Nature Chemical Biology, 8(10), 831–838.PubMedCentralCrossRefPubMed

go back to reference Huwiler, A., Brunner, J., Hummel, R., Vervoordeldonk, M., Stabel, S., van den Bosch, H., & Pfeilschifter, J. (1996). Ceramide-binding and activation defines protein kinase c-Raf as a ceramide-activated protein kinase. Proceedings of the National Academy of Sciences of the United States of America, 93(14), 6959–6963.PubMedCentralCrossRefPubMed Huwiler, A., Brunner, J., Hummel, R., Vervoordeldonk, M., Stabel, S., van den Bosch, H., & Pfeilschifter, J. (1996). Ceramide-binding and activation defines protein kinase c-Raf as a ceramide-activated protein kinase. Proceedings of the National Academy of Sciences of the United States of America, 93(14), 6959–6963.PubMedCentralCrossRefPubMed

go back to reference Zhang, Y., Yao, B., Delikat, S., Bayoumy, S., Lin, X. H., Basu, S., McGinley, M., Chan-Hui, P. Y., Lichenstein, H., & Kolesnick, R. (1997). Kinase suppressor of Ras is ceramide-activated protein kinase. Cell, 89(1), 63–72.CrossRefPubMed Zhang, Y., Yao, B., Delikat, S., Bayoumy, S., Lin, X. H., Basu, S., McGinley, M., Chan-Hui, P. Y., Lichenstein, H., & Kolesnick, R. (1997). Kinase suppressor of Ras is ceramide-activated protein kinase. Cell, 89(1), 63–72.CrossRefPubMed

go back to reference Saddoughi, S. A., & Ogretmen, B. (2013). Diverse functions of ceramide in cancer cell death and proliferation. Advances in Cancer Research, 117, 37–58.CrossRefPubMed Saddoughi, S. A., & Ogretmen, B. (2013). Diverse functions of ceramide in cancer cell death and proliferation. Advances in Cancer Research, 117, 37–58.CrossRefPubMed

go back to reference Selzner, M., Bielawska, A., Morse, M. A., Rüdiger, H. A., Sindram, D., Hannun, Y. A., & Clavien, P. A. (2001). Induction of apoptotic cell death and prevention of tumor growth by ceramide analogues in metastatic human colon cancer. Cancer Research, 61(3), 1233–1240.PubMed Selzner, M., Bielawska, A., Morse, M. A., Rüdiger, H. A., Sindram, D., Hannun, Y. A., & Clavien, P. A. (2001). Induction of apoptotic cell death and prevention of tumor growth by ceramide analogues in metastatic human colon cancer. Cancer Research, 61(3), 1233–1240.PubMed

go back to reference Jiang, Y., DiVittore, N. A., Kaiser, J. M., Shanmugavelandy, S. S., Fritz, J. L., Heakal, Y., Tagaram, H. R. S., Cheng, H., Cabot, M. C., Staveley-O’Carroll, K. F., Tran, M. A., Fox, T. E., Barth, B. M., & Kester, M. (2011). Combinatorial therapies improve the therapeutic efficacy of nanoliposomal ceramide for pancreatic cancer. Cancer Biology & Therapy, 12(7), 574–585.CrossRef Jiang, Y., DiVittore, N. A., Kaiser, J. M., Shanmugavelandy, S. S., Fritz, J. L., Heakal, Y., Tagaram, H. R. S., Cheng, H., Cabot, M. C., Staveley-O’Carroll, K. F., Tran, M. A., Fox, T. E., Barth, B. M., & Kester, M. (2011). Combinatorial therapies improve the therapeutic efficacy of nanoliposomal ceramide for pancreatic cancer. Cancer Biology & Therapy, 12(7), 574–585.CrossRef

go back to reference Ryland, L. K., Doshi, U. A., Shanmugavelandy, S. S., Fox, T. E., Aliaga, C., Broeg, K., Baab, K. T., Young, M., Khan, O., Haakenson, J. K., Jarbadan, N. R., Liao, J., Wang, H. G., Feith, D. J., Loughran Jr, T. P., Liu, X., & Kester, M. (2013). C6-ceramide nanoliposomes target the Warburg effect in chronic lymphocytic leukemia. PLoS One, 8(12), e84648.PubMedCentralCrossRefPubMed Ryland, L. K., Doshi, U. A., Shanmugavelandy, S. S., Fox, T. E., Aliaga, C., Broeg, K., Baab, K. T., Young, M., Khan, O., Haakenson, J. K., Jarbadan, N. R., Liao, J., Wang, H. G., Feith, D. J., Loughran Jr, T. P., Liu, X., & Kester, M. (2013). C6-ceramide nanoliposomes target the Warburg effect in chronic lymphocytic leukemia. PLoS One, 8(12), e84648.PubMedCentralCrossRefPubMed

go back to reference Watters, R. J., et al. (2012). Development and use of ceramide nanoliposomes in cancer. Methods in Enzymology, 508, 89–108.CrossRefPubMed Watters, R. J., et al. (2012). Development and use of ceramide nanoliposomes in cancer. Methods in Enzymology, 508, 89–108.CrossRefPubMed

go back to reference Garcia, J. G., et al. (2001). Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement. The Journal of Clinical Investigation, 108(5), 689–701.PubMedCentralCrossRefPubMed Garcia, J. G., et al. (2001). Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement. The Journal of Clinical Investigation, 108(5), 689–701.PubMedCentralCrossRefPubMed

go back to reference Singleton, P. A., Dudek, S. M., Chiang, E. T., & Garcia, J. G. N. (2005). Regulation of sphingosine 1-phosphate-induced endothelial cytoskeletal rearrangement and barrier enhancement by S1P1 receptor, PI3 kinase, Tiam1/Rac1, and alpha-actinin. The FASEB Journal, 19(12), 1646–1656.CrossRefPubMed Singleton, P. A., Dudek, S. M., Chiang, E. T., & Garcia, J. G. N. (2005). Regulation of sphingosine 1-phosphate-induced endothelial cytoskeletal rearrangement and barrier enhancement by S1P1 receptor, PI3 kinase, Tiam1/Rac1, and alpha-actinin. The FASEB Journal, 19(12), 1646–1656.CrossRefPubMed

go back to reference Watson, C., Long, J. S., Orange, C., Tannahill, C. L., Mallon, E., McGlynn, L. M., Pyne, S., Pyne, N. J., & Edwards, J. (2010). High expression of sphingosine 1-phosphate receptors, S1P1 and S1P3, sphingosine kinase 1, and extracellular signal-regulated kinase-1/2 is associated with development of tamoxifen resistance in estrogen receptor-positive breast cancer patients. The American Journal of Pathology, 177(5), 2205–2215.PubMedCentralCrossRefPubMed Watson, C., Long, J. S., Orange, C., Tannahill, C. L., Mallon, E., McGlynn, L. M., Pyne, S., Pyne, N. J., & Edwards, J. (2010). High expression of sphingosine 1-phosphate receptors, S1P1 and S1P3, sphingosine kinase 1, and extracellular signal-regulated kinase-1/2 is associated with development of tamoxifen resistance in estrogen receptor-positive breast cancer patients. The American Journal of Pathology, 177(5), 2205–2215.PubMedCentralCrossRefPubMed

go back to reference Lim, K. G., Tonelli, F., Li, Z., Lu, X., Bittman, R., Pyne, S., & Pyne, N. J. (2011). FTY720 analogues as sphingosine kinase 1 inhibitors: enzyme inhibition kinetics, allosterism, proteasomal degradation, and actin rearrangement in MCF-7 breast cancer cells. The Journal of Biological Chemistry, 286(21), 18633–18640.PubMedCentralCrossRefPubMed Lim, K. G., Tonelli, F., Li, Z., Lu, X., Bittman, R., Pyne, S., & Pyne, N. J. (2011). FTY720 analogues as sphingosine kinase 1 inhibitors: enzyme inhibition kinetics, allosterism, proteasomal degradation, and actin rearrangement in MCF-7 breast cancer cells. The Journal of Biological Chemistry, 286(21), 18633–18640.PubMedCentralCrossRefPubMed

go back to reference Ruckhaberle, E., et al. (2008). Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. Breast Cancer Research and Treatment, 112(1), 41–52.CrossRefPubMed Ruckhaberle, E., et al. (2008). Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. Breast Cancer Research and Treatment, 112(1), 41–52.CrossRefPubMed

go back to reference Watson, D. G., Tonelli, F., Alossaimi, M., Williamson, L., Chan, E., Gorshkova, I., Berdyshev, E., Bittman, R., Pyne, N. J., & Pyne, S. (2013). The roles of sphingosine kinases 1 and 2 in regulating the Warburg effect in prostate cancer cells. Cellular Signalling, 25(4), 1011–1017.PubMedCentralCrossRefPubMed Watson, D. G., Tonelli, F., Alossaimi, M., Williamson, L., Chan, E., Gorshkova, I., Berdyshev, E., Bittman, R., Pyne, N. J., & Pyne, S. (2013). The roles of sphingosine kinases 1 and 2 in regulating the Warburg effect in prostate cancer cells. Cellular Signalling, 25(4), 1011–1017.PubMedCentralCrossRefPubMed

go back to reference Warburg, O. (1956). On the origin of cancer cells. Science, 123(3191), 309–314.CrossRefPubMed Warburg, O. (1956). On the origin of cancer cells. Science, 123(3191), 309–314.CrossRefPubMed

go back to reference Kawamori, T., Osta, W., Johnson, K. R., Pettus, B. J., Bielawski, J., Tanaka, T., Wargovich, M. J., Reddy, B. S., Hannun, Y. A., Obeid, L. M., & Zhou, D. (2006). Sphingosine kinase 1 is up-regulated in colon carcinogenesis. The FASEB Journal, 20(2), 386–388.CrossRefPubMed Kawamori, T., Osta, W., Johnson, K. R., Pettus, B. J., Bielawski, J., Tanaka, T., Wargovich, M. J., Reddy, B. S., Hannun, Y. A., Obeid, L. M., & Zhou, D. (2006). Sphingosine kinase 1 is up-regulated in colon carcinogenesis. The FASEB Journal, 20(2), 386–388.CrossRefPubMed

go back to reference Greene, E. R., Huang, S., Serhan, C. N., & Panigrahy, D. (2011). Regulation of inflammation in cancer by eicosanoids. Prostaglandins & Other Lipid Mediators, 96(1–4), 27–36.CrossRef Greene, E. R., Huang, S., Serhan, C. N., & Panigrahy, D. (2011). Regulation of inflammation in cancer by eicosanoids. Prostaglandins & Other Lipid Mediators, 96(1–4), 27–36.CrossRef

go back to reference Nagahashi, M., Ramachandran, S., Kim, E. Y., Allegood, J. C., Rashid, O. M., Yamada, A., Zhao, R., Milstien, S., Zhou, H., Spiegel, S., & Takabe, K. (2012). Sphingosine-1-phosphate produced by sphingosine kinase 1 promotes breast cancer progression by stimulating angiogenesis and lymphangiogenesis. Cancer Research, 72(3), 726–735.PubMedCentralCrossRefPubMed Nagahashi, M., Ramachandran, S., Kim, E. Y., Allegood, J. C., Rashid, O. M., Yamada, A., Zhao, R., Milstien, S., Zhou, H., Spiegel, S., & Takabe, K. (2012). Sphingosine-1-phosphate produced by sphingosine kinase 1 promotes breast cancer progression by stimulating angiogenesis and lymphangiogenesis. Cancer Research, 72(3), 726–735.PubMedCentralCrossRefPubMed

go back to reference Hwang, H., Kim, E. K., Park, J., Suh, P. G., & Cho, Y. K. (2014). RhoA and Rac1 play independent roles in lysophosphatidic acid-induced ovarian cancer chemotaxis. Integrative Biology (Camb), 6(3), 267–276.CrossRef Hwang, H., Kim, E. K., Park, J., Suh, P. G., & Cho, Y. K. (2014). RhoA and Rac1 play independent roles in lysophosphatidic acid-induced ovarian cancer chemotaxis. Integrative Biology (Camb), 6(3), 267–276.CrossRef

go back to reference Tsujiuchi, T., Hirane, M., Dong, Y., & Fukushima, N. (2014). Diverse effects of LPA receptors on cell motile activities of cancer cells. Journal of Receptor and Signal Transduction Research, 34(3), 149–153.CrossRefPubMed Tsujiuchi, T., Hirane, M., Dong, Y., & Fukushima, N. (2014). Diverse effects of LPA receptors on cell motile activities of cancer cells. Journal of Receptor and Signal Transduction Research, 34(3), 149–153.CrossRefPubMed

go back to reference Willier, S., Butt, E., & Grunewald, T. G. (2013). Lysophosphatidic acid (LPA) signalling in cell migration and cancer invasion: a focussed review and analysis of LPA receptor gene expression on the basis of more than 1700 cancer microarrays. Biology of the Cell, 105(8), 317–333.CrossRefPubMed Willier, S., Butt, E., & Grunewald, T. G. (2013). Lysophosphatidic acid (LPA) signalling in cell migration and cancer invasion: a focussed review and analysis of LPA receptor gene expression on the basis of more than 1700 cancer microarrays. Biology of the Cell, 105(8), 317–333.CrossRefPubMed

go back to reference Matayoshi, S., et al. (2013). Lysophosphatidic acid receptor 4 signaling potentially modulates malignant behavior in human head and neck squamous cell carcinoma cells. International Journal of Oncology, 42(5), 1560–1568.PubMedCentralCrossRefPubMed Matayoshi, S., et al. (2013). Lysophosphatidic acid receptor 4 signaling potentially modulates malignant behavior in human head and neck squamous cell carcinoma cells. International Journal of Oncology, 42(5), 1560–1568.PubMedCentralCrossRefPubMed

go back to reference Yang, D., et al. (2013). Migration of gastric cancer cells in response to lysophosphatidic acid is mediated by LPA receptor 2. Oncology Letters, 5(3), 1048–1052.PubMedCentralCrossRefPubMed Yang, D., et al. (2013). Migration of gastric cancer cells in response to lysophosphatidic acid is mediated by LPA receptor 2. Oncology Letters, 5(3), 1048–1052.PubMedCentralCrossRefPubMed

go back to reference Oda, S. K., Strauch, P., Fujiwara, Y., al-Shami, A., Oravecz, T., Tigyi, G., Pelanda, R., & Torres, R. M. (2013). Lysophosphatidic acid inhibits CD8 T cell activation and control of tumor progression. Cancer Immunology Research, 1(4), 245–255.PubMedCentralCrossRefPubMed Oda, S. K., Strauch, P., Fujiwara, Y., al-Shami, A., Oravecz, T., Tigyi, G., Pelanda, R., & Torres, R. M. (2013). Lysophosphatidic acid inhibits CD8 T cell activation and control of tumor progression. Cancer Immunology Research, 1(4), 245–255.PubMedCentralCrossRefPubMed

go back to reference Ogden, C. L., et al. Prevalence of obesity among adults and youth: United States, 2011-2014. NCHS Data Brief, 2015(219), 1–8. Ogden, C. L., et al. Prevalence of obesity among adults and youth: United States, 2011-2014. NCHS Data Brief, 2015(219), 1–8.

go back to reference Ma, Y., Yang, Y., Wang, F., Zhang, P., Shi, C., Zou, Y., & Qin, H. (2013). Obesity and risk of colorectal cancer: a systematic review of prospective studies. PLoS One, 8(1), e53916.PubMedCentralCrossRefPubMed Ma, Y., Yang, Y., Wang, F., Zhang, P., Shi, C., Zou, Y., & Qin, H. (2013). Obesity and risk of colorectal cancer: a systematic review of prospective studies. PLoS One, 8(1), e53916.PubMedCentralCrossRefPubMed

go back to reference Wang, F., & Xu, Y. (2014). Body mass index and risk of renal cell cancer: a dose-response meta-analysis of published cohort studies. International Journal of Cancer, 135(7), 1673–1686.CrossRefPubMed Wang, F., & Xu, Y. (2014). Body mass index and risk of renal cell cancer: a dose-response meta-analysis of published cohort studies. International Journal of Cancer, 135(7), 1673–1686.CrossRefPubMed

go back to reference Chen, Y., Wang, X., Wang, J., Yan, Z., & Luo, J. (2012). Excess body weight and the risk of primary liver cancer: an updated meta-analysis of prospective studies. European Journal of Cancer, 48(14), 2137–2145.CrossRefPubMed Chen, Y., Wang, X., Wang, J., Yan, Z., & Luo, J. (2012). Excess body weight and the risk of primary liver cancer: an updated meta-analysis of prospective studies. European Journal of Cancer, 48(14), 2137–2145.CrossRefPubMed

go back to reference Dougan, M. M., Hankinson, S. E., Vivo, I. D., Tworoger, S. S., Glynn, R. J., & Michels, K. B. (2015). Prospective study of body size throughout the life-course and the incidence of endometrial cancer among premenopausal and postmenopausal women. International Journal of Cancer, 137(3), 625–637.PubMedCentralCrossRefPubMed Dougan, M. M., Hankinson, S. E., Vivo, I. D., Tworoger, S. S., Glynn, R. J., & Michels, K. B. (2015). Prospective study of body size throughout the life-course and the incidence of endometrial cancer among premenopausal and postmenopausal women. International Journal of Cancer, 137(3), 625–637.PubMedCentralCrossRefPubMed

go back to reference Srinivas, G. V., Namala, S., Ananthaneni, A., Puneeth, H. K., & Devi, B. S. (2013). Evaluation and correlation of serum lipid profile in oral and gastrointestinal cancer patients. Journal of International Oral Health, 5(6), 72–77.PubMed Srinivas, G. V., Namala, S., Ananthaneni, A., Puneeth, H. K., & Devi, B. S. (2013). Evaluation and correlation of serum lipid profile in oral and gastrointestinal cancer patients. Journal of International Oral Health, 5(6), 72–77.PubMed

go back to reference Martin, L. J., et al. (2015). Serum lipids, lipoproteins, and risk of breast cancer: a nested case-control study using multiple time points. Journal of the National Cancer Institute, 107(5). Martin, L. J., et al. (2015). Serum lipids, lipoproteins, and risk of breast cancer: a nested case-control study using multiple time points. Journal of the National Cancer Institute, 107(5).

go back to reference Ulmer, H., et al. (2009). Serum triglyceride concentrations and cancer risk in a large cohort study in Austria. British Journal of Cancer, 101(7), 1202–1206.PubMedCentralCrossRefPubMed Ulmer, H., et al. (2009). Serum triglyceride concentrations and cancer risk in a large cohort study in Austria. British Journal of Cancer, 101(7), 1202–1206.PubMedCentralCrossRefPubMed

go back to reference Esposito, K., Chiodini, P., Capuano, A., Bellastella, G., Maiorino, M. I., & Giugliano, D. (2014). Metabolic syndrome and endometrial cancer: a meta-analysis. Endocrine, 45(1), 28–36.CrossRefPubMed Esposito, K., Chiodini, P., Capuano, A., Bellastella, G., Maiorino, M. I., & Giugliano, D. (2014). Metabolic syndrome and endometrial cancer: a meta-analysis. Endocrine, 45(1), 28–36.CrossRefPubMed

go back to reference Zhang, C., Yu, L., Xu, T., Hao, Y., Zhang, X., Liu, Z., Xiao, Y., Wang, X., & Zeng, Q. (2013). Association of dyslipidemia with renal cell carcinoma: a 1ratio2 matched case-control study. PLoS One, 8(3), e59796.PubMedCentralCrossRefPubMed Zhang, C., Yu, L., Xu, T., Hao, Y., Zhang, X., Liu, Z., Xiao, Y., Wang, X., & Zeng, Q. (2013). Association of dyslipidemia with renal cell carcinoma: a 1ratio2 matched case-control study. PLoS One, 8(3), e59796.PubMedCentralCrossRefPubMed

go back to reference Saito, K., Arai, E., Maekawa, K., Ishikawa, M., Fujimoto, H., Taguchi, R., Matsumoto, K., Kanai, Y., & Saito, Y. (2016). Lipidomic signatures and associated transcriptomic profiles of clear cell renal cell carcinoma. Scientific Reports, 6, 28932.PubMedCentralCrossRefPubMed Saito, K., Arai, E., Maekawa, K., Ishikawa, M., Fujimoto, H., Taguchi, R., Matsumoto, K., Kanai, Y., & Saito, Y. (2016). Lipidomic signatures and associated transcriptomic profiles of clear cell renal cell carcinoma. Scientific Reports, 6, 28932.PubMedCentralCrossRefPubMed

go back to reference Nelson, E. R., Wardell, S. E., Jasper, J. S., Park, S., Suchindran, S., Howe, M. K., Carver, N. J., Pillai, R. V., Sullivan, P. M., Sondhi, V., Umetani, M., Geradts, J., & McDonnell, D. P. (2013). 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science, 342(6162), 1094–1098.PubMedCentralCrossRefPubMed Nelson, E. R., Wardell, S. E., Jasper, J. S., Park, S., Suchindran, S., Howe, M. K., Carver, N. J., Pillai, R. V., Sullivan, P. M., Sondhi, V., Umetani, M., Geradts, J., & McDonnell, D. P. (2013). 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science, 342(6162), 1094–1098.PubMedCentralCrossRefPubMed

go back to reference Li, P., Zhang, H., Chen, J., Shi, Y., Cai, J., Yang, J., & Wu, Y. (2014). Association between dietary antioxidant vitamins intake/blood level and risk of gastric cancer. International Journal of Cancer, 135(6), 1444–1453.CrossRefPubMed Li, P., Zhang, H., Chen, J., Shi, Y., Cai, J., Yang, J., & Wu, Y. (2014). Association between dietary antioxidant vitamins intake/blood level and risk of gastric cancer. International Journal of Cancer, 135(6), 1444–1453.CrossRefPubMed

go back to reference Klein, E. A., Thompson, I. M., Tangen, C. M., Crowley, J. J., Lucia, M. S., Goodman, P. J., Minasian, L. M., Ford, L. G., Parnes, H. L., Gaziano, J. M., Karp, D. D., Lieber, M. M., Walther, P. J., Klotz, L., Parsons, J. K., Chin, J. L., Darke, A. K., Lippman, S. M., Goodman, G. E., Meyskens, F. L., & Baker, L. H. (2011). Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA, 306(14), 1549–1556.PubMedCentralCrossRefPubMed Klein, E. A., Thompson, I. M., Tangen, C. M., Crowley, J. J., Lucia, M. S., Goodman, P. J., Minasian, L. M., Ford, L. G., Parnes, H. L., Gaziano, J. M., Karp, D. D., Lieber, M. M., Walther, P. J., Klotz, L., Parsons, J. K., Chin, J. L., Darke, A. K., Lippman, S. M., Goodman, G. E., Meyskens, F. L., & Baker, L. H. (2011). Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA, 306(14), 1549–1556.PubMedCentralCrossRefPubMed

go back to reference Sayin, V. I., et al. (2014). Antioxidants accelerate lung cancer progression in mice. Science Translational Medicine, 6(221), 221ra15.CrossRefPubMed Sayin, V. I., et al. (2014). Antioxidants accelerate lung cancer progression in mice. Science Translational Medicine, 6(221), 221ra15.CrossRefPubMed

go back to reference Juanola-Falgarona, M., Salas-Salvadó, J., Martínez-González, M. Á., Corella, D., Estruch, R., Ros, E., Fitó, M., Arós, F., Gómez-Gracia, E., Fiol, M., Lapetra, J., Basora, J., Lamuela-Raventós, R. M., Serra-Majem, L., Pintó, X., Muñoz, M. Á., Ruiz-Gutiérrez, V., Fernández-Ballart, J., & Bulló, M. (2014). Dietary intake of vitamin K is inversely associated with mortality risk. The Journal of Nutrition, 144(5), 743–750.CrossRefPubMed Juanola-Falgarona, M., Salas-Salvadó, J., Martínez-González, M. Á., Corella, D., Estruch, R., Ros, E., Fitó, M., Arós, F., Gómez-Gracia, E., Fiol, M., Lapetra, J., Basora, J., Lamuela-Raventós, R. M., Serra-Majem, L., Pintó, X., Muñoz, M. Á., Ruiz-Gutiérrez, V., Fernández-Ballart, J., & Bulló, M. (2014). Dietary intake of vitamin K is inversely associated with mortality risk. The Journal of Nutrition, 144(5), 743–750.CrossRefPubMed

go back to reference Faust, P. L., & Kovacs, W. J. (2014). Cholesterol biosynthesis and ER stress in peroxisome deficiency. Biochimie, 98, 75–85.CrossRefPubMed Faust, P. L., & Kovacs, W. J. (2014). Cholesterol biosynthesis and ER stress in peroxisome deficiency. Biochimie, 98, 75–85.CrossRefPubMed

go back to reference Bui, D. T., Nicolas, J., Maksimenko, A., Desmaële, D., & Couvreur, P. (2014). Multifunctional squalene-based prodrug nanoparticles for targeted cancer therapy. Chemical Communications (Camb), 50(40), 5336–5338.CrossRef Bui, D. T., Nicolas, J., Maksimenko, A., Desmaële, D., & Couvreur, P. (2014). Multifunctional squalene-based prodrug nanoparticles for targeted cancer therapy. Chemical Communications (Camb), 50(40), 5336–5338.CrossRef

go back to reference Desmaele, D., Gref, R., & Couvreur, P. (2012). Squalenoylation: a generic platform for nanoparticular drug delivery. Journal of Controlled Release, 161(2), 609–618.CrossRefPubMed Desmaele, D., Gref, R., & Couvreur, P. (2012). Squalenoylation: a generic platform for nanoparticular drug delivery. Journal of Controlled Release, 161(2), 609–618.CrossRefPubMed

go back to reference Couvreur, P., Stella, B., Reddy, L. H., Hillaireau, H., Dubernet, C., Desmaële, D., Lepêtre-Mouelhi, S., Rocco, F., Dereuddre-Bosquet, N., Clayette, P., Rosilio, V., Marsaud, V., Renoir, J. M., & Cattel, L. (2006). Squalenoyl nanomedicines as potential therapeutics. Nano Letters, 6(11), 2544–2548.CrossRefPubMed Couvreur, P., Stella, B., Reddy, L. H., Hillaireau, H., Dubernet, C., Desmaële, D., Lepêtre-Mouelhi, S., Rocco, F., Dereuddre-Bosquet, N., Clayette, P., Rosilio, V., Marsaud, V., Renoir, J. M., & Cattel, L. (2006). Squalenoyl nanomedicines as potential therapeutics. Nano Letters, 6(11), 2544–2548.CrossRefPubMed

go back to reference Maksimenko, A., Alami, M., Zouhiri, F., Brion, J. D., Pruvost, A., Mougin, J., Hamze, A., Boissenot, T., Provot, O., Desmaële, D., & Couvreur, P. (2014). Therapeutic modalities of squalenoyl nanocomposites in colon cancer: an ongoing search for improved efficacy. ACS Nano, 8(3), 2018–2032.PubMedCentralCrossRefPubMed Maksimenko, A., Alami, M., Zouhiri, F., Brion, J. D., Pruvost, A., Mougin, J., Hamze, A., Boissenot, T., Provot, O., Desmaële, D., & Couvreur, P. (2014). Therapeutic modalities of squalenoyl nanocomposites in colon cancer: an ongoing search for improved efficacy. ACS Nano, 8(3), 2018–2032.PubMedCentralCrossRefPubMed

go back to reference Tan, L. T. (2013). Pharmaceutical agents from filamentous marine cyanobacteria. Drug Discovery Today, 18(17–18), 863–871.CrossRefPubMed Tan, L. T. (2013). Pharmaceutical agents from filamentous marine cyanobacteria. Drug Discovery Today, 18(17–18), 863–871.CrossRefPubMed

go back to reference Chiorazzi, A., Nicolini, G., Canta, A., Oggioni, N., Rigolio, R., Cossa, G., Lombardi, R., Roglio, I., Cervellini, I., Lauria, G., Melcangi, R. C., Bianchi, R., Crippa, D., & Cavaletti, G. (2009). Experimental epothilone B neurotoxicity: results of in vitro and in vivo studies. Neurobiology of Disease, 35(2), 270–277.CrossRefPubMed Chiorazzi, A., Nicolini, G., Canta, A., Oggioni, N., Rigolio, R., Cossa, G., Lombardi, R., Roglio, I., Cervellini, I., Lauria, G., Melcangi, R. C., Bianchi, R., Crippa, D., & Cavaletti, G. (2009). Experimental epothilone B neurotoxicity: results of in vitro and in vivo studies. Neurobiology of Disease, 35(2), 270–277.CrossRefPubMed

go back to reference Guzman, E. A., et al. (2017). Inhibition of IL-8 secretion on BxPC-3 and MIA PaCa-2 cells and induction of cytotoxicity in pancreatic cancer cells with marine natural products. Anti-Cancer Drugs, 28(2), 153–160.CrossRefPubMed Guzman, E. A., et al. (2017). Inhibition of IL-8 secretion on BxPC-3 and MIA PaCa-2 cells and induction of cytotoxicity in pancreatic cancer cells with marine natural products. Anti-Cancer Drugs, 28(2), 153–160.CrossRefPubMed

go back to reference Chou, T. C., Zhang, X. G., Harris, C. R., Kuduk, S. D., Balog, A., Savin, K. A., Bertino, J. R., & Danishefsky, S. J. (1998). Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel. Proceedings of the National Academy of Sciences of the United States of America, 95(26), 15798–15802.PubMedCentralCrossRefPubMed Chou, T. C., Zhang, X. G., Harris, C. R., Kuduk, S. D., Balog, A., Savin, K. A., Bertino, J. R., & Danishefsky, S. J. (1998). Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel. Proceedings of the National Academy of Sciences of the United States of America, 95(26), 15798–15802.PubMedCentralCrossRefPubMed

go back to reference Issa, M. E., Hall, S. R., Dupuis, S. N., Graham, C. L., Jakeman, D. L., & Goralski, K. B. (2014). Jadomycins are cytotoxic to ABCB1-, ABCC1-, and ABCG2-overexpressing MCF7 breast cancer cells. Anti-Cancer Drugs, 25(3), 255–269.CrossRefPubMed Issa, M. E., Hall, S. R., Dupuis, S. N., Graham, C. L., Jakeman, D. L., & Goralski, K. B. (2014). Jadomycins are cytotoxic to ABCB1-, ABCC1-, and ABCG2-overexpressing MCF7 breast cancer cells. Anti-Cancer Drugs, 25(3), 255–269.CrossRefPubMed

go back to reference Choi, E. S., Jung, J. Y., Lee, J. S., Park, J. H., Cho, N. P., & Cho, S. D. (2013). Myeloid cell leukemia-1 is a key molecular target for mithramycin A-induced apoptosis in androgen-independent prostate cancer cells and a tumor xenograft animal model. Cancer Letters, 328(1), 65–72.CrossRefPubMed Choi, E. S., Jung, J. Y., Lee, J. S., Park, J. H., Cho, N. P., & Cho, S. D. (2013). Myeloid cell leukemia-1 is a key molecular target for mithramycin A-induced apoptosis in androgen-independent prostate cancer cells and a tumor xenograft animal model. Cancer Letters, 328(1), 65–72.CrossRefPubMed

go back to reference Arthur, J. C., Perez-Chanona, E., Muhlbauer, M., Tomkovich, S., Uronis, J. M., Fan, T. J., Campbell, B. J., Abujamel, T., Dogan, B., Rogers, A. B., Rhodes, J. M., Stintzi, A., Simpson, K. W., Hansen, J. J., Keku, T. O., Fodor, A. A., & Jobin, C. (2012). Intestinal inflammation targets cancer-inducing activity of the microbiota. Science, 338(6103), 120–123.PubMedCentralCrossRefPubMed Arthur, J. C., Perez-Chanona, E., Muhlbauer, M., Tomkovich, S., Uronis, J. M., Fan, T. J., Campbell, B. J., Abujamel, T., Dogan, B., Rogers, A. B., Rhodes, J. M., Stintzi, A., Simpson, K. W., Hansen, J. J., Keku, T. O., Fodor, A. A., & Jobin, C. (2012). Intestinal inflammation targets cancer-inducing activity of the microbiota. Science, 338(6103), 120–123.PubMedCentralCrossRefPubMed

go back to reference Serhan, C. N. (2014). Pro-resolving lipid mediators are leads for resolution physiology. Nature, 510(7503), 92–101.PubMedCentralCrossRefPubMed Serhan, C. N. (2014). Pro-resolving lipid mediators are leads for resolution physiology. Nature, 510(7503), 92–101.PubMedCentralCrossRefPubMed

go back to reference Serhan, C. N., & Chiang, N. (2013). Resolution phase lipid mediators of inflammation: agonists of resolution. Current Opinion in Pharmacology, 13(4), 632–640.PubMedCentralCrossRefPubMed Serhan, C. N., & Chiang, N. (2013). Resolution phase lipid mediators of inflammation: agonists of resolution. Current Opinion in Pharmacology, 13(4), 632–640.PubMedCentralCrossRefPubMed

go back to reference Serhan, C. N. (2007). Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annual Review of Immunology, 25, 101–137.CrossRefPubMed Serhan, C. N. (2007). Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annual Review of Immunology, 25, 101–137.CrossRefPubMed

go back to reference Serhan, C. N., et al. (2011). Novel anti-inflammatory—pro-resolving mediators and their receptors. Current Topics in Medicinal Chemistry, 11(6), 629–647.PubMedCentralCrossRefPubMed Serhan, C. N., et al. (2011). Novel anti-inflammatory—pro-resolving mediators and their receptors. Current Topics in Medicinal Chemistry, 11(6), 629–647.PubMedCentralCrossRefPubMed

go back to reference Serhan, C. N., & Savill, J. (2005). Resolution of inflammation: the beginning programs the end. Nature Immunology, 6(12), 1191–1197.CrossRefPubMed Serhan, C. N., & Savill, J. (2005). Resolution of inflammation: the beginning programs the end. Nature Immunology, 6(12), 1191–1197.CrossRefPubMed

go back to reference Krishnamoorthy, S., Recchiuti, A., Chiang, N., Fredman, G., & Serhan, C. N. (2012). Resolvin D1 receptor stereoselectivity and regulation of inflammation and proresolving microRNAs. The American Journal of Pathology, 180(5), 2018–2027.PubMedCentralCrossRefPubMed Krishnamoorthy, S., Recchiuti, A., Chiang, N., Fredman, G., & Serhan, C. N. (2012). Resolvin D1 receptor stereoselectivity and regulation of inflammation and proresolving microRNAs. The American Journal of Pathology, 180(5), 2018–2027.PubMedCentralCrossRefPubMed

go back to reference Sun, Y. P., Oh, S. F., Uddin, J., Yang, R., Gotlinger, K., Campbell, E., Colgan, S. P., Petasis, N. A., & Serhan, C. N. (2007). Resolvin D1 and its aspirin-triggered 17R epimer. Stereochemical assignments, anti-inflammatory properties, and enzymatic inactivation. The Journal of Biological Chemistry, 282(13), 9323–9334.CrossRefPubMed Sun, Y. P., Oh, S. F., Uddin, J., Yang, R., Gotlinger, K., Campbell, E., Colgan, S. P., Petasis, N. A., & Serhan, C. N. (2007). Resolvin D1 and its aspirin-triggered 17R epimer. Stereochemical assignments, anti-inflammatory properties, and enzymatic inactivation. The Journal of Biological Chemistry, 282(13), 9323–9334.CrossRefPubMed

go back to reference Serhan, C. N., Hong, S., Gronert, K., Colgan, S. P., Devchand, P. R., Mirick, G., & Moussignac, R. L. (2002). Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. The Journal of Experimental Medicine, 196(8), 1025–1037.PubMedCentralCrossRefPubMed Serhan, C. N., Hong, S., Gronert, K., Colgan, S. P., Devchand, P. R., Mirick, G., & Moussignac, R. L. (2002). Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. The Journal of Experimental Medicine, 196(8), 1025–1037.PubMedCentralCrossRefPubMed

go back to reference Serhan, C. N. (2005). Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution. Prostaglandins, Leukotrienes, and Essential Fatty Acids, 73(3–4), 141–162.CrossRefPubMed Serhan, C. N. (2005). Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution. Prostaglandins, Leukotrienes, and Essential Fatty Acids, 73(3–4), 141–162.CrossRefPubMed

go back to reference Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, 144(5), 646–674.CrossRefPubMed Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, 144(5), 646–674.CrossRefPubMed

go back to reference Mantovani, A. (2005). Cancer: inflammation by remote control. Nature, 435(7043), 752–753.CrossRefPubMed Mantovani, A. (2005). Cancer: inflammation by remote control. Nature, 435(7043), 752–753.CrossRefPubMed

go back to reference Guerra, C., & Barbacid, M. (2013). Genetically engineered mouse models of pancreatic adenocarcinoma. Molecular Oncology, 7(2), 232–247.PubMedCentralCrossRefPubMed Guerra, C., & Barbacid, M. (2013). Genetically engineered mouse models of pancreatic adenocarcinoma. Molecular Oncology, 7(2), 232–247.PubMedCentralCrossRefPubMed

go back to reference Ridker, P. M., MacFadyen, J. G., Thuren, T., Everett, B. M., Libby, P., Glynn, R. J., Ridker, P., Lorenzatti, A., Krum, H., Varigos, J., Siostrzonek, P., Sinnaeve, P., Fonseca, F., Nicolau, J., Gotcheva, N., Genest, J., Yong, H., Urina-Triana, M., Milicic, D., Cifkova, R., Vettus, R., Koenig, W., Anker, S. D., Manolis, A. J., Wyss, F., Forster, T., Sigurdsson, A., Pais, P., Fucili, A., Ogawa, H., Shimokawa, H., Veze, I., Petrauskiene, B., Salvador, L., Kastelein, J., Cornel, J. H., Klemsdal, T. O., Medina, F., Budaj, A., Vida-Simiti, L., Kobalava, Z., Otasevic, P., Pella, D., Lainscak, M., Seung, K. B., Commerford, P., Dellborg, M., Donath, M., Hwang, J. J., Kultursay, H., Flather, M., Ballantyne, C., Bilazarian, S., Chang, W., East, C., Everett, B., Forgosh, L., Glynn, R., Harris, B., Libby, P., Ligueros, M., Thuren, T., Bohula, E., Charmarthi, B., Cheng, S., Chou, S., Danik, J., McMahon, G., Maron, B., Ning, M. M., Olenchock, B., Pande, R., Perlstein, T., Pradhan, A., Rost, N., Singhal, A., Taqueti, V., Wei, N., Burris, H., Cioffi, A., Dalseg, A. M., Ghosh, N., Gralow, J., Mayer, T., Rugo, H., Fowler, V., Limaye, A. P., Cosgrove, S., Levine, D., Lopes, R., Scott, J., Thuren, T., Ligueros, M., Hilkert, R., Tamesby, G., Mickel, C., Manning, B., Woelcke, J., Tan, M., Manfreda, S., Ponce, T., Kam, J., Saini, R., Banker, K., Salko, T., Nandy, P., Tawfik, R., O'Neil, G., Manne, S., Jirvankar, P., Lal, S., Nema, D., Jose, J., Collins, R., Bailey, K., Blumenthal, R., Colhoun, H., Gersh, B., & Glynn, R. J. (2017). Effect of interleukin-1beta inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet, 390(10105), 1833–1842.CrossRefPubMed Ridker, P. M., MacFadyen, J. G., Thuren, T., Everett, B. M., Libby, P., Glynn, R. J., Ridker, P., Lorenzatti, A., Krum, H., Varigos, J., Siostrzonek, P., Sinnaeve, P., Fonseca, F., Nicolau, J., Gotcheva, N., Genest, J., Yong, H., Urina-Triana, M., Milicic, D., Cifkova, R., Vettus, R., Koenig, W., Anker, S. D., Manolis, A. J., Wyss, F., Forster, T., Sigurdsson, A., Pais, P., Fucili, A., Ogawa, H., Shimokawa, H., Veze, I., Petrauskiene, B., Salvador, L., Kastelein, J., Cornel, J. H., Klemsdal, T. O., Medina, F., Budaj, A., Vida-Simiti, L., Kobalava, Z., Otasevic, P., Pella, D., Lainscak, M., Seung, K. B., Commerford, P., Dellborg, M., Donath, M., Hwang, J. J., Kultursay, H., Flather, M., Ballantyne, C., Bilazarian, S., Chang, W., East, C., Everett, B., Forgosh, L., Glynn, R., Harris, B., Libby, P., Ligueros, M., Thuren, T., Bohula, E., Charmarthi, B., Cheng, S., Chou, S., Danik, J., McMahon, G., Maron, B., Ning, M. M., Olenchock, B., Pande, R., Perlstein, T., Pradhan, A., Rost, N., Singhal, A., Taqueti, V., Wei, N., Burris, H., Cioffi, A., Dalseg, A. M., Ghosh, N., Gralow, J., Mayer, T., Rugo, H., Fowler, V., Limaye, A. P., Cosgrove, S., Levine, D., Lopes, R., Scott, J., Thuren, T., Ligueros, M., Hilkert, R., Tamesby, G., Mickel, C., Manning, B., Woelcke, J., Tan, M., Manfreda, S., Ponce, T., Kam, J., Saini, R., Banker, K., Salko, T., Nandy, P., Tawfik, R., O'Neil, G., Manne, S., Jirvankar, P., Lal, S., Nema, D., Jose, J., Collins, R., Bailey, K., Blumenthal, R., Colhoun, H., Gersh, B., & Glynn, R. J. (2017). Effect of interleukin-1beta inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet, 390(10105), 1833–1842.CrossRefPubMed

go back to reference Ye, Y., Scheff, N. N., Bernabé, D., Salvo, E., Ono, K., Liu, C., Veeramachaneni, R., Viet, C. T., Viet, D. T., Dolan, J. C., & Schmidt, B. L. (2018). Anti-cancer and analgesic effects of resolvin D2 in oral squamous cell carcinoma. Neuropharmacology, 139, 182–193.CrossRefPubMed Ye, Y., Scheff, N. N., Bernabé, D., Salvo, E., Ono, K., Liu, C., Veeramachaneni, R., Viet, C. T., Viet, D. T., Dolan, J. C., & Schmidt, B. L. (2018). Anti-cancer and analgesic effects of resolvin D2 in oral squamous cell carcinoma. Neuropharmacology, 139, 182–193.CrossRefPubMed

go back to reference Shepelin, D., Korzinkin, M., Vanyushina, A., Aliper, A., Borisov, N., Vasilov, R., Zhukov, N., Sokov, D., Prassolov, V., Gaifullin, N., Zhavoronkov, A., Bhullar, B., & Buzdin, A. (2016). Molecular pathway activation features linked with transition from normal skin to primary and metastatic melanomas in human. Oncotarget, 7(1), 656–670.CrossRefPubMed Shepelin, D., Korzinkin, M., Vanyushina, A., Aliper, A., Borisov, N., Vasilov, R., Zhukov, N., Sokov, D., Prassolov, V., Gaifullin, N., Zhavoronkov, A., Bhullar, B., & Buzdin, A. (2016). Molecular pathway activation features linked with transition from normal skin to primary and metastatic melanomas in human. Oncotarget, 7(1), 656–670.CrossRefPubMed

go back to reference Zhong, X., Lee, H. N., & Surh, Y. J. (2018). RvD1 inhibits TNFalpha-induced c-Myc expression in normal intestinal epithelial cells and destabilizes hyper-expressed c-Myc in colon cancer cells. Biochemical and Biophysical Research Communications, 496(2), 316–323.CrossRefPubMed Zhong, X., Lee, H. N., & Surh, Y. J. (2018). RvD1 inhibits TNFalpha-induced c-Myc expression in normal intestinal epithelial cells and destabilizes hyper-expressed c-Myc in colon cancer cells. Biochemical and Biophysical Research Communications, 496(2), 316–323.CrossRefPubMed

go back to reference Halder, R. C., et al. (2015). Curcuminoids and omega-3 fatty acids with anti-oxidants potentiate cytotoxicity of natural killer cells against pancreatic ductal adenocarcinoma cells and inhibit interferon gamma production. Frontiers in Physiology, 6, 129.PubMedCentralCrossRefPubMed Halder, R. C., et al. (2015). Curcuminoids and omega-3 fatty acids with anti-oxidants potentiate cytotoxicity of natural killer cells against pancreatic ductal adenocarcinoma cells and inhibit interferon gamma production. Frontiers in Physiology, 6, 129.PubMedCentralCrossRefPubMed

go back to reference Kuang, H., et al. (2016). Resolvin D1 and E1 alleviate the progress of hepatitis toward liver cancer in long-term concanavalin A-induced mice through inhibition of NF-kappaB activity. Oncology Reports, 35(1), 307–317.CrossRefPubMed Kuang, H., et al. (2016). Resolvin D1 and E1 alleviate the progress of hepatitis toward liver cancer in long-term concanavalin A-induced mice through inhibition of NF-kappaB activity. Oncology Reports, 35(1), 307–317.CrossRefPubMed

go back to reference Prevete, N., Liotti, F., Illiano, A., Amoresano, A., Pucci, P., de Paulis, A., & Melillo, R. M. (2017). Formyl peptide receptor 1 suppresses gastric cancer angiogenesis and growth by exploiting inflammation resolution pathways. Oncoimmunology, 6(4), e1293213.PubMedCentralCrossRefPubMed Prevete, N., Liotti, F., Illiano, A., Amoresano, A., Pucci, P., de Paulis, A., & Melillo, R. M. (2017). Formyl peptide receptor 1 suppresses gastric cancer angiogenesis and growth by exploiting inflammation resolution pathways. Oncoimmunology, 6(4), e1293213.PubMedCentralCrossRefPubMed

go back to reference Lee, H. J., Park, M. K., Lee, E. J., & Lee, C. H. (2013). Resolvin D1 inhibits TGF-beta1-induced epithelial mesenchymal transition of A549 lung cancer cells via lipoxin A4 receptor/formyl peptide receptor 2 and GPR32. The International Journal of Biochemistry & Cell Biology, 45(12), 2801–2807.CrossRef Lee, H. J., Park, M. K., Lee, E. J., & Lee, C. H. (2013). Resolvin D1 inhibits TGF-beta1-induced epithelial mesenchymal transition of A549 lung cancer cells via lipoxin A4 receptor/formyl peptide receptor 2 and GPR32. The International Journal of Biochemistry & Cell Biology, 45(12), 2801–2807.CrossRef

go back to reference Liu, Y., Yuan, X., Li, W., Cao, Q., & Shu, Y. (2016). Aspirin-triggered resolvin D1 inhibits TGF-beta1-induced EMT through the inhibition of the mTOR pathway by reducing the expression of PKM2 and is closely linked to oxidative stress. International Journal of Molecular Medicine, 38(4), 1235–1242.CrossRefPubMed Liu, Y., Yuan, X., Li, W., Cao, Q., & Shu, Y. (2016). Aspirin-triggered resolvin D1 inhibits TGF-beta1-induced EMT through the inhibition of the mTOR pathway by reducing the expression of PKM2 and is closely linked to oxidative stress. International Journal of Molecular Medicine, 38(4), 1235–1242.CrossRefPubMed

go back to reference Simoes, R. L., et al. (2017). Lipoxin A4 selectively programs the profile of M2 tumor-associated macrophages which favour control of tumor progression. International Journal of Cancer, 140(2), 346–357.CrossRefPubMed Simoes, R. L., et al. (2017). Lipoxin A4 selectively programs the profile of M2 tumor-associated macrophages which favour control of tumor progression. International Journal of Cancer, 140(2), 346–357.CrossRefPubMed

go back to reference Chen, Y., Hao, H., He, S., Cai, L., Li, Y., Hu, S., Ye, D., Hoidal, J., Wu, P., & Chen, X. (2010). Lipoxin A4 and its analogue suppress the tumor growth of transplanted H22 in mice: the role of antiangiogenesis. Molecular Cancer Therapeutics, 9(8), 2164–2174.CrossRefPubMed Chen, Y., Hao, H., He, S., Cai, L., Li, Y., Hu, S., Ye, D., Hoidal, J., Wu, P., & Chen, X. (2010). Lipoxin A4 and its analogue suppress the tumor growth of transplanted H22 in mice: the role of antiangiogenesis. Molecular Cancer Therapeutics, 9(8), 2164–2174.CrossRefPubMed

go back to reference Stenke, L., Edenius, C., Samuelsson, J., & Lindgren, J. A. (1991). Deficient lipoxin synthesis: a novel platelet dysfunction in myeloproliferative disorders with special reference to blastic crisis of chronic myelogenous leukemia. Blood, 78(11), 2989–2995.PubMed Stenke, L., Edenius, C., Samuelsson, J., & Lindgren, J. A. (1991). Deficient lipoxin synthesis: a novel platelet dysfunction in myeloproliferative disorders with special reference to blastic crisis of chronic myelogenous leukemia. Blood, 78(11), 2989–2995.PubMed

go back to reference Wang, C., Xiao, M., Liu, X., Ni, C., Liu, J., Erben, U., & Qin, Z. (2013). IFN-gamma-mediated downregulation of LXA4 is necessary for the maintenance of nonresolving inflammation and papilloma persistence. Cancer Research, 73(6), 1742–1751.CrossRefPubMed Wang, C., Xiao, M., Liu, X., Ni, C., Liu, J., Erben, U., & Qin, Z. (2013). IFN-gamma-mediated downregulation of LXA4 is necessary for the maintenance of nonresolving inflammation and papilloma persistence. Cancer Research, 73(6), 1742–1751.CrossRefPubMed

go back to reference Wang, Z., Cheng, Q., Tang, K., Sun, Y., Zhang, K., Zhang, Y., Luo, S., Zhang, H., Ye, D., & Huang, B. (2015). Lipid mediator lipoxin A4 inhibits tumor growth by targeting IL-10-producing regulatory B (Breg) cells. Cancer Letters, 364(2), 118–124.CrossRefPubMed Wang, Z., Cheng, Q., Tang, K., Sun, Y., Zhang, K., Zhang, Y., Luo, S., Zhang, H., Ye, D., & Huang, B. (2015). Lipid mediator lipoxin A4 inhibits tumor growth by targeting IL-10-producing regulatory B (Breg) cells. Cancer Letters, 364(2), 118–124.CrossRefPubMed

go back to reference Chandrasekharan, J. A., Huang, X. M., Hwang, A. C., & Sharma-Walia, N. (2016). Altering the anti-inflammatory lipoxin microenvironment: a new insight into Kaposi’s sarcoma-associated herpesvirus pathogenesis. Journal of Virology, 90(24), 11020–11031.PubMedCentralCrossRefPubMed Chandrasekharan, J. A., Huang, X. M., Hwang, A. C., & Sharma-Walia, N. (2016). Altering the anti-inflammatory lipoxin microenvironment: a new insight into Kaposi’s sarcoma-associated herpesvirus pathogenesis. Journal of Virology, 90(24), 11020–11031.PubMedCentralCrossRefPubMed

go back to reference Serhan, C. N., Yang, R., Martinod, K., Kasuga, K., Pillai, P. S., Porter, T. F., Oh, S. F., & Spite, M. (2009). Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. The Journal of Experimental Medicine, 206(1), 15–23.PubMedCentralCrossRefPubMed Serhan, C. N., Yang, R., Martinod, K., Kasuga, K., Pillai, P. S., Porter, T. F., Oh, S. F., & Spite, M. (2009). Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. The Journal of Experimental Medicine, 206(1), 15–23.PubMedCentralCrossRefPubMed

go back to reference Dalli, J., Vlasakov, I., Riley, I. R., Rodriguez, A. R., Spur, B. W., Petasis, N. A., Chiang, N., & Serhan, C. N. (2016). Maresin conjugates in tissue regeneration biosynthesis enzymes in human macrophages. Proceedings of the National Academy of Sciences of the United States of America, 113(43), 12232–12237.PubMedCentralCrossRefPubMed Dalli, J., Vlasakov, I., Riley, I. R., Rodriguez, A. R., Spur, B. W., Petasis, N. A., Chiang, N., & Serhan, C. N. (2016). Maresin conjugates in tissue regeneration biosynthesis enzymes in human macrophages. Proceedings of the National Academy of Sciences of the United States of America, 113(43), 12232–12237.PubMedCentralCrossRefPubMed